Confidential DePuy Synthes Joint Reconstruction 
Revision Date: 19Feb-2018                                                                     Protocol: CIP [ZIP_CODE] REV B 
                                                                         Page 1 of 58 
  
DePuy Synthes Joint Reconstruction 
CLINICAL RESEARCH 
 
 
CLINICAL INVESTIGATION PLAN (CIP) 
 
 
                                                                              TITLE 
Comparison of Alignment achieved using Single-Use versus Reusable Instrumentation in Total Knee Arthroplasty (TKA): A Prospective, Non-Randomized Multi-Center Investigation. 
 
This document is a confidential communication of  DePuy Synthes Joint Reconstruction. The recipi[INVESTIGATOR_453271] n will be published or disclosed without prior 
written approval of DePuy Synthes Joint Reconstructi on except that this document may be disclosed to 
appropriate oversight authorities or duly authoriz ed representatives of the U.S. Food and Drug 
Administration or other responsible regulatory auth orities under the condition that they are requested to 
keep it confidential.  
 
Clinical Investigation  Plan Number: [ZIP_CODE]  
Country:  Worldwide Stud y 
CIP Prepared By:   
 
 
 
 
[CONTACT_453298]:  Revision B 
Clinical Investigation Sponsor: DePuy Synthes Joint Reconstruction a division of DePuy Orthopaedics, Inc.
 
PO Box [ADDRESS_578018]  
Warsaw, IN   4658 1-0988 
 
 
 
 
 
 
   

Confidential DePuy Synthes Joint Reconstruction 
Revision Date: 19Feb-2018                                                                     Protocol: CIP [ZIP_CODE] REV B 
                                                                         Page 2 of 58 
 PROTOCOL SIGNATURE [CONTACT_453329]-Use  versus Reusable Instrumentation in Total Knee 
Arthroplasty (TKA): A Prospective, Non-Randomized Multi-Center Investigation. 
PROTOCOL [ZIP_CODE]  
Document   
Type/Revision Protocol/Exhibit  Effective Date 
 
Original                 #1    Protocol/Exhibits Rev A May 28, 2015 
Administrative     #2                               Protocol/Exhibits Rev B February 19, 2018 
 Principal Investigator:   I have read this protocol and agree to conduct this clinical investigation in  accordance with the 
design and specific provisions outlined herein.  I understand the protocol and I understand I am so lely responsible to ensure the investigation is 
conducted in accordance with Good Clinical Prac tices (GCP), applicable country regulations, the 
Declaration of Helsinki, the signed clinical study contract with DePuy Synthes Joint Reconstruction, and with the protocol outlined herein.  
 
I will conduct this study as outlined therein and will make reasonable effort to complete the study within the time period designated by  [CONTACT_453299]. 
 I will provide copi[INVESTIGATOR_453272]. I w ill discuss this material with them to ensure they 
are fully informed regarding the devi ce and the conduct of the study.  
 
I will fulfill the requirements of my Institutional Review Board (IRB)/Ethics Committee (EC), or other oversight committee, to ensure complete and conti nual oversight of this clinical investigation.   I 
will use an Informed Consent Document approved by [CONTACT_453300]/EC.  
 
I agree to report all information or data in accord ance with the protocol and I agree to report any 
serious adverse events, device related adverse ev ents, or procedure related adverse events as 
defined in this protocol to DePuy Synthes Joint Re construction and comply with all adverse events 
reporting requirements of my reviewing IRB/EC. 
 
I agree to permit DePuy Synthes Joint Reconstructi on, its authorized representatives, my reviewing 
IRB/EC, and any regulatory authority/body access to al l records relating to the clinical investigation.  
 

Confidential  DePuy Synthes Joint Reconstruction  
Revision Date: 19Feb -2018                                                                     Proto col: CIP [ADDRESS_578019] read and understood this protocol and its associated 
amendments or attachments, and will accept respective revisions or amendments provided by 
[CONTACT_453301] J oint Reconstruction.  
 
 
_______________________________________                        _______________  
Principal Investigator               [INVESTIGATOR_453273]: 19Feb-2018                                                                     Protocol: CIP [ZIP_CODE] REV B 
                                                                         Page 4 of 58 
  
Table of Contents 
 
COMPARISON OF ALIGNMENT ACHIEVED USING SINGLE -USE VERSUS RE[LOCATION_003]BLE INSTRUMENTATION IN TOTAL KNEE 
ARTHROPLASTY (TKA):  A PROSPECTIVE , NON-RANDOMIZED MULTI-CENTER INVESTIGATION . ............................................ [ADDRESS_578020] ARE AS FOLLOWS : ............................................................................ [ADDRESS_578021] PARTICIPATION  .......................................................................... 25 
Confidential DePuy Synthes Joint Reconstruction 
Revision Date: 19Feb-2018                                                                     Protocol: CIP [ZIP_CODE] REV B 
                                                                         Page 5 of 58 
 8.4.1  Preoperative Screen Failures/Withdrawals ................................................................................... 25  
8.4.2  Intra-operative Withdrawal .................................................................................................... ...... 26  
8.4.3  Enrollment Replacem ent Rules .................................................................................................. .... 27  
8.4.4  Postoperative Withdrawal ...................................................................................................... ...... 27  
8.4.5  Revisions / Reoper ations ...................................................................................................... ......... [ADDRESS_578022] to Follow-up .................................................................................. 2 9 
9 RISK ANALYSIS ................................................................................................................. ................. 31  
 A DVERSE EVENT DETERMINATION  ................................................................................................................ 31 
 N ON-REPORTABLE ADVERSE EVENTS - SPONSOR ONLY .................................................................................. 31 
 S TUDY RELATED RISKS / REPORTABLE ADVERSE EVENTS  .................................................................................. [ADDRESS_578023] (IRB) / Ethi cs Committee (EC) Reporting. ........................................... 39  
9.7.3  Regulatory reporting requirements ............................................................................................. .. 39 
10 STATISTICAL METHODOLOGY ....................................................................................................... ..... 40  
 S TUDY DESIGN  .............................................................................................................................. ........ 40 
 T REATMENT ASSIGNMENT  ...................................................................................................................... 40 
 L EVELS OF SIGNIFICANCE  ......................................................................................................................... 40 
 I NTERVAL WINDOWS  ............................................................................................................................. 40 
 H ANDLING OF MISSING DATA .................................................................................................................. 41 
 P RIMARY AND SECONDARY ENDPOINTS  ..................................................................................................... 41 
 H YPOTHESES  .............................................................................................................................. ........... 41 
 A NALYSIS SETS .............................................................................................................................. ........ 42 
 S AMPLE SIZE JUSTIFICATION  .................................................................................................................... 42 
 A NALYSIS PLAN .............................................................................................................................. ....... 43 
 I NTERIM ANALYSIS  .............................................................................................................................. ... 44 
11 DEVICE DESCRIPTION ............................................................................................................ ............ 45  
 I NSTRUMENTS  .............................................................................................................................. ......... 45 
11.1.1  Reusable Instruments .......................................................................................................... .......... 45  
11.1.2  The ATTUNE Single Use Instruments (SUI) .................................................................................... 45  
 I MPLANTS  .............................................................................................................................. .............. 45 
12 INVESTIGATOR RESPONSIBILITIES AND GOOD CLINICAL PRACTICES .................................................... 48  
 IRB/  ETHICS COMMITTEE APPROVAL  ........................................................................................................ [ADDRESS_578024] OF DEVICE INVENTORY  ............................................................................................................... 50 
 C ASE REPORT FORM COMPLETION AND DATA SUBMISSION  .......................................................................... 50 
Confidential DePuy Synthes Joint Reconstruction 
Revision Date: 19Feb-2018                                                                     Protocol: CIP [ZIP_CODE] REV B 
                                                                         Page 6 of 58 
 
 P ROTOCOL ADHERENCE  .......................................................................................................................... 51 
 CIP  AMENDMENTS  .............................................................................................................................. .. 51 
 I NVESTIGATOR REPORTING RESPONSIBILITIES  ............................................................................................. 51 
 I NVESTIGATOR SITE FILE.......................................................................................................................... 53 
 R EGULATORY REQUIREMENTS  .................................................................................................................. 53 
 I NVESTIGATOR STUDY TERMINATION  ........................................................................................................ 53 
13 SPONSOR OBLIGATIONS ........................................................................................................... ......... 54  
 IRB/EC  APPROVAL  .............................................................................................................................. .. 54 
 I NVESTIGATOR TRAINING , PRE-INVESTIGATIONAL VISIT ................................................................................ 54 
 S TUDY MONITORING  ..............................................................................................................................  54 
SPONSOR OVERSIGHT WILL BE MAINTAINED PER SPONSOR POLICIES AND PROCEDURES .  ON SITE MONITORING WILL BE DONE AT 
THE DISCRETION OF THE SPONSOR . SHOULD A MONITORING VISIT BE REQUIRED , THE SPONSOR WILL WORK WITH THE SITE TO 
DETERMINE THE DATE (S). ............................................................................................................................ .......... [ADDRESS_578025]  MEDICAL RECORDS . ....................................................................................................... 54 
 L ABELING  .............................................................................................................................. ............... 54 
 S PONSOR STUDY TERMINATION  ............................................................................................................... 54 
 S PONSOR REPORTING RESPONSIBILITIES  .................................................................................................... 55 
 F INANCIAL AGREEMENT  .......................................................................................................................... 55 
 P UBLICATION POLICY AND PUBLIC DISCLOSURE  .......................................................................................... 55 
 I NSURANCE  .............................................................................................................................. ............. 55 
14 REFERENCES .................................................................................................................... ................. 56  
15 CLINICAL INVESTIGATIONAL PLAN EXHIBITS....................................................................................... 5 8 
 
Confidential  DePuy Synthes Joint Reconstruction  
Revision Date: 19Feb -2018                                                                     Proto col: CIP [ADDRESS_578026] European Norm  
21 CFR      Code of Federal Regulation:  Title 21  
CE  Confor mité Européenne  
CIP  Clinical Investigational Plan  
CR   Cruciate Retaining  
CRF  Case Report Form (paper)   
DVT  Deep Vein Thrombosis   
EC  Ethics Committee  
eCRF   Electronic Case Report Form   
EMEA   Europe/Middle East/ Asia -Pacific  
EU  European Union  
FB  Fixed  Bearing  
FDA  Food and Drug Administration  
GCP  Good Clinical Practice  
HTO   High Tibial Osteotomy  
ICD  Informed Consent Document  
IRB  Institutional Review Board  
ISO  International Organization for Standardization  
IRR  Independent Radiographic Reviewer                            
ITT  Intent To Treat  
MEDDEV  Medical Device Guidance Document(s)  
NIDJD   Non -inflammatory Degenerative Joint Disease  
OR  Operating Room  
PHI  Personal Health Information  
PI  [INVESTIGATOR_453274] -Market Clinical Follow -up  
Post-op  Post -operative  
PP  Per Protocol Analysis  
Confidential  DePuy Synthes Joint Reconstruction  
Revision Date: 19Feb -2018                                                                     Proto col: CIP [ADDRESS_578027]  
SAE  Serious Adverse Event  
SAS®   Statistical Analysis System  
SUI  Single Use Instruments  
TKA  Total Knee Arthroplasty  
UADE   Unanticipated Adverse Device Effect  
[LOCATION_006]  [LOCATION_008]  
US  [LOCATION_002]  
[LOCATION_003]DE   Unanticipated Serious Adverse Device Effect  
UTO   Upper Tibial Osteotomy  (See also HTO)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Confidential  DePuy Synthes Joint Reconstruction  
Revision Date: 19Feb -2018                                                                     Proto col: CIP [ZIP_CODE] REV B  
                                                                         Page 9 of 58 
 2 SUMMARY  
TITLE:  Comparison of Alignment  achieved  using Single -Use versus Reusable 
Instrumentation  in Total Knee Arthroplasty (TKA) : A Prospective, Non -
Randomized Multi -Center  Investigation . 
Short Title:  SUI vs. RUI  
Protocol 
Number:  [ZIP_CODE]  
Treatment 
Device:  Single Use Instruments (SUI)  for implantation of ATTUNE ® primary TKA. Four 
implant  configurations are permitted:  Cruciate Retaining  Fixed Bearing  (CR FB),  
Cruciate Retaining R otating Platform (CR RP), Posterior S tabilizing Fixed Bearing 
(PS FB) and Posterior Stabilizing Rotating P latform (PS RP) configurations .  Each site 
will be restricted to using either Cruciate Retaining configurations or Posterior 
Stabilizing Configurations for both treatment and control groups.  
Control 
Device:  Reusable Instruments (RUI) for implantation of  ATTUNE  primary TKA.  Four  
implan t configurations are permitted:  Cruciate Retaining Fixed Bearing (CR FB),  
Cruciate Retaining Rotating Platform (CR RP), Posterior Stabilizing Fixed Bearing 
(PS FB) and Posterior Stabilizing Rotating Platform (PS RP) configurations.  Each site 
will be rest ricted to using either Cruciate Retaining configurations or Posterior 
Stabilizing Configurations for both treatment and control groups.  
Intended 
Use:  The intended use for the instrumentation and device, applicable to this study, is as 
follows:  
Candidates for total knee  replacement include patients with severely painful 
and/or severely disabl ing Non-inflammatory Degenerative Joint Disease (NIDJD) 
resulting from osteoarthritis (OA) or post -traumatic arthritis.  
Primary 
Objective:  To determine whether the mec hanical axis alignment achieved with SUI 
instrumentation is non -inferior to the alignment achieved  with RUI 
instrumentation.   
Secondary 
Objectives  • To compare individual component alignment achieved with SUI vs. RUI of 
individual components in the fronta l and sagittal planes, specifically: distal 
femoral varus -valgus  (FM) , proximal tibial varus -valgus (TM) ,  femoral 
component flexion and tibial slope.   
• To compare the type and frequency of  adverse events  
Study 
Design:  Prospective, comparative, sequential , non -randomized, multi -center, controlled 
study design.  Level  of evidence: Level II IA 
Number of 
Sites:  [ADDRESS_578028] 
Population:  Male and female Subjects who are candidates for primary, total knee arthr oplasty 
between 22 and 80 years of age, inclusive, with noninflammatory degenerative 
joint disease ( NIDJD ) resulting from osteoarthritis (OA) or post -traumatic arthritis .   
Sample Size:  A total of 88  Subjects  will be  enrolled in the investigation (44 treatment Subjects 
and 44 control Subjects).  
                                                           
A Levels of Evid ence for Primary Research Question  
 
  
Confidential  DePuy Synthes Joint Reconstruction  
Revision Date: 19Feb -2018                                                                     Proto col: CIP [ZIP_CODE] REV B  
                                                                         Page 10 of 58 
 TITLE:  Comparison of Alignment  achieved  using Single -Use versus Reusable 
Instrumentation  in Total Knee Arthroplasty (TKA) : A Prospective, Non -
Randomized Multi -Center  Investigation . 
Study 
Duration:  The estimated duration of this study is 13 months: [ADDRESS_578029] -operative follow -up. 
Procedure 
Schedule:  Demographic data will be collected preoperatively.  Surgica l data will be collected 
intraoperatively.   Post –operatively , radiographic data will be collected at 
approximately 90 days . 
Safety:  All adverse events will be collected from the time of surgery  through to the end of 
the study or the time when that Subjec t is withdrawn from the study . A listing of 
expected, procedure -related, early postoperative adverse events (AEs) will be 
provided and such events will not need to be recorded. The type and frequency of 
recorded AEs will be analyzed.  
  
  
Confidential DePuy Synthes Joint Reconstruction 
Revision Date: 19Feb-2018                                                                     Protocol: CIP [ZIP_CODE] REV B 
                                                                         Page 11 of 58 
 
Time and Events Table 
Event / Visit  Pre-Op Surgery  Post-Op  
Required Timing (days)  -180d to 
include day 
[ADDRESS_578030] History eCRF C   
Surgical Procedure 
xComplete Operative Details eCRF 
xComplete Device Log eCRF   
C 
C  
Radiographs 
xHip to Ankle Long Film     
  R* 
xAP View  R  R 
xLateral View    R 
Complete Adverse Event eCRF  A  A
Complete End of Study/Withdrawal  A A C 
Advise the Subject when they will next be seen Yes Yes  
C= Case Report Form to be completed and subm itted in the Electronic data capture system 
R= Radiograph  obtained and submitted 
R*, For the purposes of  this investigation this radiograph will only be performed when 
the Subject can achieve full le g extension (±5°). 
A= As needed 
 
 
  
Confidential DePuy Synthes Joint Reconstruction 
Revision Date: 19Feb-2018                                                                     Protocol: CIP [ZIP_CODE] REV B 
                                                                         Page 12 of 58 
 3INTRODUCTION 
Background 
Alignment 
 
Successful total knee arthroplasty relies on proper positioning of prosthetic components to restore 
the mechanical axis of the lower extremity. It is wi dely accepted that proper alignment is an important 
factor in the success and longevity of total knee arthroplasties [1-4]. Mechanical axis alignment is 
defined as the line drawn from the center of the femoral head through the center of the knee and ankle. The knee is in proper alignment when thes e three points are collinear in the frontal plane
[1] . 
Many authors have observed that the correct alignm ent of the lower limb is correlated with clinical 
success in total knee arthroplasty [2-7].  
 
Operating Room (OR)  Efficiency                                                                                                                         
In this era of capi[INVESTIGATOR_453275], cost containment is assuming greater 
importance in health care. Consequently, operating room efficiency has become higher priority for many institutions
 [8]. As patient volume increases and hospi[INVESTIGATOR_453276] a bottleneck in providing efficient, high quality patient care.  Optimizing OR performance 
without compromising safe and high-quality heal th care for patients is an important goal. 
There are a number of studies aimed at increasing oper ating room efficiency and controlling operating 
room costs while striving to provide high-quality, technologically advanced surgical services.  Often 
the focus is on streamlining the existing steps that are involved in delivering patient care preoperatively, intraoperatively, and postoperatively 
[10]. This need for improved delivery of care is 
further critical when one recognizes the increasing number of patients needing TKA. Improved surgical 
instruments are one factor that may improve OR effici ency and an  approach is to introduce Single-
Use instruments.  
 An important aspect of the delivery of surgical care  is the time required to prepare the operating room 
prior to the procedure as well as the turnover ti me at the conclusion of the surgery.  Preparation 
timeline for every surgical procedure is at risk from  various delays.  Unwanted delays have occurred 
related to unavailable sterile instruments,  holes foun d in the sterile wrap of sterilized instruments, 
the time required to flash steriliz e an instrument requested last minute, etc.   Prepackaged sterilized 
Single-Use instruments may help to resolve some of  these unwanted delays.  Additionally, when single 
use instruments are combined with preoperative templating to define implant sizing, there should be 
a substantial reduction in the quantity of instru ments brought to the OR (Figure 1). Single use 
instruments provide a completely clean and sterile in strument for every patient, which is used once 
and disposed of, removing the need for lengthy decontamination processes
[13].   
 
  
  
Confidential  DePuy Synthes Joint Reconstruction  
Revision Date: 19Feb -2018                                                                     Proto col: CIP [ZIP_CODE] REV B  
                                                                         Page 13 of 58 
 Figure 3-1: ATTUNE TKA Instrumentation  (left to right): Reusable  instrumentation ; and  Single Use 
instrumentation shown  
        

  
Confidential DePuy Synthes Joint Reconstruction 
Revision Date: 19Feb-2018                                                                     Protocol: CIP [ZIP_CODE] REV B 
                                                                         Page 14 of 58 
 4RATIONALE 
Study Rationale 
A pre-requisite for SUI adoption is to confir m that  the mechanical axis alignment achi eved with                  
single use instruments is non-inferior to the alignmen t achieved with ATTUNE reusable instruments .    
Study Design Rationale 
The study was designed as comparative, sequential , non-randomized, multi-center, such that each 
site has an equal number of Subjects in each trea tment group, SUI and RUI. The follow-up period of 
approximately [ADDRESS_578031] Subjects to be able to achieve 
full leg extension (within ± 5°), a requirement fo r obtaining suitable weight-bearing hip-to-ankle 
radiographs for analysis of alignmen t.  The mechanical axis alignment will be assessed at the 3 month 
follow-up by [CONTACT_388836].  The se quential design (that is at each site all RUI cases 
will be completed before doing any of the SUI cases)  is set up to ensure that with the control group 
(RUI), current status of OR efficiency is captured ra ther than this being influenced by [CONTACT_453302]. 
 
Rationale of Endpoints 
Successful total knee arthroplasty relies on proper positioning of prosthetic components to restore 
the mechanical axis of the lower extremity. It is wi dely accepted that proper alignment is an important 
factor in the success and longevity of total knee arthroplasties [1-4].  A goal of 0° ± 3° mechanical axis 
alignment was chosen because the Investigators in this study confirmed they regularly aim for this 
target.    
 
Rationale of Study Population 
Subjects with NIDJD and determined to be suitable for a cemented, primary TKA with the ATTUNE implant are targeted as this study is on surgical instruments to implant a cemented, primary ATTUNE 
implant.   Narrowing the indications to exclud e inflammatory arthritis was done to have more 
homogeneity in the population, including bone quali ty that could possibly influence bone resections 
with the two instrument types. 
 
  
Confidential DePuy Synthes Joint Reconstruction 
Revision Date: 19Feb-2018                                                                     Protocol: CIP [ZIP_CODE] REV B 
                                                                         Page 15 of 58 
 5SUBJECT DEFINITION 
Male and female Subjects, aged 22-80 years, inclusive, with Non-Inflammatory Degenerative Joint 
Disease (NIDJD) resulting from osteoarthritis (OA) or post-traumatic arthritis and suitable candidates 
for primary, total knee arthroplasty using an ATTUNE system are eligible for enrollment in this study.  Subjects who do not meet all of the inclusion criteria or meet any of the exclusion criteria are automatically excluded from study consideration and participation.  Subjects, who meet all entry criteria and are properly consented, may be excluded from participation because of:  
xSurgeon preference/medical opi[INVESTIGATOR_1649] (under very limited conditions not to introduce Investigator 
bias). 
xWithdrawal of consent from study participation.  
Inclusion Criteria 
Subjects meeting all of the following specific criteria will be considered for participation in the study:  
 
a)Subjects with severely painful and/or severel y disabling Non-inflammatory Degenerative Joint 
Disease (NIDJD) resulting from osteoarthritis (OA) or post-traumatic arthritis.  
b)Subject is male or female and between the ages of 22 and 80 years old, inclusive.  
 
c)Subject requires a primary total knee replacement and is considered by [CONTACT_453303].   
 
d)Subject, who, in the opi[INVESTIGATOR_453277], is suitable for implantation using either RUI 
or SUI instrumentation.  
 
e)Subject is able to speak and read English to fa cilitate comprehension of the Informed Consent 
Document.   
f)Subject has given voluntary, written informed consent to participate in this clinical 
investigation and has authorized  the transfer of his/her information to DePuy Synthes Joint 
Reconstruction. 
 
g)Subject, in the opi[INVESTIGATOR_689], is ab le to understand this clinical investigation and 
is willing and able to perform all study procedures and follow-up visits and co-operate with 
investigational procedures. 
 
Exclusion Criteria 
Subjects will be excluded from participation if they meet any of the following criteria:  
 
a)The Subject has, in the opi[INVESTIGATOR_689], a severe deformity that will hinder 
achieving a mechanical axis alignment target of 0°  ±   3°. 
  
Confidential DePuy Synthes Joint Reconstruction 
Revision Date: 19Feb-2018                                                                     Protocol: CIP [ZIP_CODE] REV B 
                                                                         Page 16 of 58 
  
b)The Subject has, in the opi[INVESTIGATOR_689], an existing condition that would 
compromise their participation and follow-up in this study.    
c)The Subject has, in the opi[INVESTIGATOR_66286], a flexion deformity that will not allow 
for 0° extension postoperatively.   
d)The Subject is a woman who is pregnant or lactating. 
 
e)The Subject, in the opi[INVESTIGATOR_689] , is a drug or alcohol abuser (in the last 5 
years) or has a psychological disorder that could affect follow-up care or treatment outcomes.  
f)The Subject has participated in a clinical inve stigation with an investigational product in 
the last 3 months. 
 
g)The Subject is currently involved in any person al injury litigation, medical-legal or worker’s 
compensations claims. 
 h)The Subject has previous prosthetic knee replacement  (any type including 
unicompartmental, total knee arthroplasty, pa tellofemoral arthroplasty or ipsilateral 
UTO/HTO) of the affected knee or a previous patellectomy.  
 i)The Subject presents with ankylosis of th e hip joint on the side to be treated. 
 
j)The Subject had a contralateral TKA and that knee was previously entered into the study.
B 
 
k)The Subject requires simultaneous bilateral total knee replacements.C 
 l)Any case in which Computer-Assisted Surgery (CAS) or TruMatch (or any other type of 
Custom Patient Instruments) is to be used, or any additional instrumentation are to be 
used for bone resections that are not provided as part of the ATTUNE RUI or SUI Instrument kits. 
 
m)The Subject requires a device not specified in the protocol or the surgeon determines that 
the ATTUNE Knee System is not a suitable treatment. 
Definition of Subject Enrollment 
As described in additional detail in Section 8.[ADDRESS_578032]: 
 
9 Provided written informed consent to participate in this Investigation, which includes authorization 
of the release of their Personal  Health Information (PHI).   
                                                           
B Having both knees from one Subject in the study could confound the data. 
C As the study involves measuring the time take n for stages of surgery a simultaneous bilateral 
procedure would confound this dataset (would always take longer) 
  
Confidential DePuy Synthes Joint Reconstruction 
Revision Date: 19Feb-2018                                                                     Protocol: CIP [ZIP_CODE] REV B 
                                                                         Page 17 of 58 
 6OBJECTIVES AND HYPOTHESIS 
Primary Objective 
To determine whether the mechanical axis alignmentD achieved with SUI instrumentation is non-
inferior to the alignment achieved with RUI instrume ntation.  Mechanical axis alignment is defined as 
the line drawn from the center of the femoral head  through the center of the knee and ankle and will 
be measured from weight bearing long-leg (51”) Anteroposterior (AP) radiographs, taken approximately [ADDRESS_578033]-op (when subject ha s reached full knee extension) and read by [CONTACT_453304].   
Secondary Objectives 
xTo compare alignment achieved with SUI vs. RUI of individual componen ts in the frontal and 
sagittal planes, specifically: distal femoral varus-valgus (FM) , proximal tibial varus-valgus (TM),  femoral component flexion and tibial slope. 
xTo compare the type and frequency of  adverse events, from the time of surgery through to 
withdrawal of a subject or the end of the stud y (includes serious adverse events, and device 
and/or procedure-related adverse events), between the SUI and RUI instrument groups.  
Exploratory Objectives 
xTo compare SUI and RUI operating room times from OR set-up through OR clean down as 
detailed in Table 8-3 of Section 8.3.3. 
xTo determine whether SUI provides opportunity to reduce the incidence of minor procedural 
obstacles during the time in the OR.  
xTo compare Surgeon satisfaction of SUI instrumentation to RUI instrumentation. 
 The primary and secondary clinical endpoints and th e relevant statistical analyses are described in 
Section 10.6  
Hypothesis 
Hypothesis: If Single Use Instruments are used to implant an ATTUNE Total Knee, the alignment 
achieved will be non-inferior to that achieved with Reusable Instruments for the same procedure. 
 
See Section 10.7 for further details on study hypotheses. 
                                                           
D During preparation of this protocol discussions with  the sites to be involved in this study  confirmed 
that all 4  sites regularly plan to achieve 0° ±  3° mechanical axis alignment. Exceptions to this are only in rare cases of  extreme deformity. The study has therefore been designed with this in mind and 
collection of pre-operative  plans are not required for the study. 
 
  
Confidential  DePuy Synthes Joint Reconstruction  
Revision Date: 19Feb -2018                                                                     Proto col: CIP [ZIP_CODE] REV B  
                                                                         Page 18 of 58 
 7 STUDY DESIGN  
This study is designed as a prospective , comparative, sequential, non -randomized, multi -center, 
controlled clinical inv estigation .  
 
There will be 4 centers  worldwide  that will recruit a total of 88  Subjects ( 44 Treatment Subjects and 
44 Control Subjects) .  A complete description of the methods for determining sample size is contained 
in Section 10.9. Initially,  the Subjects w ill be evenly distributed across the four sites; therefore it is 
expected that each site will recruit 22 Subjects  (11 Control  followed sequentially by 11 Treatment  
Subjects ).  In between the Control and Treatment Subjects , a learning curve is permitted for  the use 
of SUI.  
 
• The Control group  will consist of 44 Subjects, 11 per site and the surgical procedure for these 
Subjects  will be performed using Reusable Instruments (RUI).  
• The Treatment group  will consist of 44 Subjects, 11 per site and the surgical pr ocedure for 
these Subjects  will be performed using Single Use Instruments (SUI).  
 
At each site the [ADDRESS_578034] 
surgery in the Treatment group. For a given site , either Cruciate Retaini ng or Posterior Stabilising 
configurations will be used ; consistent with their standard of care .  Within a given CR site, the 
Investigator may choose to implant either the CR FB or CR RP.  Similarly, within a given PS site, the 
Investigator may choose to i mplant either the PS FB or PS RP .  Randomiz ation is not being applied  in 
this study in order to isolate and learn if there are changes in  OR efficiency with SUI under normal 
operating room procedures . 
 
One surgeon at each site will complet e all RUI and SUI  surgical  cases including the learning curve. No 
Sub-Investigators will be permitted  to perform surgery  to avoid possible confounding issues with 
varying surgical process.  All sites will have previously completed their learning curve with the ATTUNE  
Prim ary Implant implanted using RUI prior to enrolling the 1st patient. Then after the completion of 
all RUI study cases,  a learning curve will be permitted for the use of SUI.  The duration of the SUI 
learning curve is anticipated to be approximately [ADDRESS_578035] of care. TruMatch technology or any other type of Custom Patient Instruments are  
not permitted.  Similarly Computer -Assisted Surgery (CAS) is not permitted within the study.  The 
procedures must be performed  using only the instrum entation provided (SUI or RUI) and standard 
surgical methods, without additional tools that could confound the key research question of this study  
(for example, instrumentation that helps perform bone resections) . 
 
The Sponsor will monitor overall project enrollment. Cohort reallocation  during the RUI phase  only  
may be done in order to maintain project timelines. The Sponsor  can authorize  a shift of a group of 
Subjects from one site to another to maintain project timelines.   For example , the Sponsor can r educe 
the cohort of a slow -enrolling RUI site to a faster -enrolling RUI site  and t he faster -enrolling RUI  site 
will assume responsibility for the reallocated RUI cohort and the same number  of SUI Subjects.   
  
Confidential DePuy Synthes Joint Reconstruction 
Revision Date: 19Feb-2018                                                                     Protocol: CIP [ZIP_CODE] REV B 
                                                                         Page 19 of 58 
 8PROTOCOL 
The sequence of events for a Subject are as follows: 
xIf the Patient is thought to be generally eligib le, the Patient is invited to participate and the 
informed consent procedure is followed 
xThe Subject is screened for eligibility against the Protocol Inclusion/Exclusion criteria 
xIf the Subject meets the Protocol Inclusion/Exclusion criteria, a subject history is taken 
xWithin 180 days from initiating the consent pr ocedure TKA surgery is performed during which 
operative details, timepoints of key stages of  the procedure, instrument and device details, 
and any intraoperative complications are captu red on eCRFs for submission and subsequent 
analysis. 
xApproximately 90 days (+/-60 days) post -surgery weight bearing long-leg (51”) 
Anteroposterior (AP) radiographs are taken and any postoperative complications collected.  
Radiographs are to be anonymiz ed and sent to the Independent Radiographic Reviewer (IRR) 
for analysis. 
Subject Enrollment            
No study-related procedure or form associated with this study can be completed until written 
informed consent is obtained for that Subject. (see  Section 5.[ADDRESS_578036] Enrollment). 
8.2.1Subject Screening 
All Patients who present with NIDJD affecting the knee, and are candidates for primary, cemented 
TKA, and who generally meet the study requirements, wi ll be screened for eligibility and will be listed 
on the Screening and Enrollment Log in order to document that the Subject selection was unbiased. 
The date of screening, the results of screening (included or not) and the primary reason for not including the patient ( e.g., does not satisfy eligibility criteria,  not interested in participating) will be 
recorded on this log. The original log is to be retained at the Site and a copy sent to the Sponsor 
regularly during enrollment.  A flowchart demonstr ating the screening process and definition of 
enrollment is illustrated in Figure 8-1.  Eligible Patients who agree to participate in the study will be required to sign an Informed Consent 
Document prior to any study related procedures being done.  After signing the Informed Consent,  
study Subjects are defined as “enrolled” and site will complete the non-standard of care pre-operative data collection.  
 
It is expected that complete data collection will be  obtained for all enrolled Subjects, with the only 
exception being a Subject who is subsequently withdrawn. See Section 8.[ADDRESS_578037] Participation  (Withdrawal) for details. 
  
  
Confidential  DePuy Synthes Joint Reconstruction  
Revision Date: 19Feb -2018                                                                     Proto col: CIP [ADDRESS_578038] is included in the study without adequate informed consent 
being provided.  Failure to obtain and properly document th is process is in violation of  BS EN ISO 
[ZIP_CODE] , the Declarat ion of Helsinki , and this study protocol.   
All informed consent documents (ICD) must have favorable opi[INVESTIGATOR_1100]/ EC (Section 12.1 ).  
Consent of a Subject needs to be from the subject themsel ves and documented on an Informed 
Consent Document in the primary language of the Subject.   
 
Screening, consenting and enrollment are illustrated in Figure 8 -1.  The Investigator or trained 
designee preliminarily screen s to determine if a patient generall y meets the eligibility criteria for the 
study  (item 2 in flowchart , Figure 8 -1).  If so, the  Investigator or trained designee  shall offer study 
participation to those patients  (item 3 in flowchart , Figure 8 -1). If the patient agrees to participate 
s/he si gns the informed consent document .   
 
               Table 8-1: Key Elements of Consent Process  
Key Element of Consent Process (item 4 of flowchart)  
The Investigator or designee shall confirm the Subject unde rstands each of the following 
points of the study:  
 
• The purpose of the study,  
• The potential risks or adverse events that are posed by [CONTACT_453305],  
• The potential risks or adverse events directly related to study participation,  
• Possibility of failure and  the need for subsequent treatment(s),  
• Alternative procedures/treatments available to the Subject,  
• Requirements of the study including rehabilitation and follow -up visits,  
• All of the Subject’s rights as a participant in the clinical investigation.  
 
Followi ng the explanation of the study intent, the Investigator or trained designee shall 
offer to answer any of the Subject’s questions.  If the Subject then agrees to participate, 
his or her willingness must be documented via a signature [CONTACT_453330]/EC’ s 
approved ICD and this document countersigned and dated by [CONTACT_453306].  
 
 
Upon successful completion of consent process, the Patient is enrolled and is identified as a Study 
Subject ( item s 5 in flowchart , Figure 8 -1).  The Investigator or t rained designee will assess eligibility 
per Sections 5.1 & 5.2 ( item 6 in flowchart , Figure 8 -1). 
 
Acquiring Consent on Day of Surgery:   If the Informed Consent Document signatures are acquired on 
the day of surgery, a time stamp on the signature [CONTACT_453331] r equired to support that consent was 
obtained from the study Subject prior to any treatment related and/or mood altering medications 
being administered.   A time stamp is not required where consent is obtained on a day prior to surgery.   
  
  
Confidential DePuy Synthes Joint Reconstruction 
Revision Date: 19Feb-2018                                                                     Protocol: CIP [ZIP_CODE] REV B 
                                                                         Page 21 of 58 
 Figure 8-1: Screening and Enrollment Process 
 
1) Review Surgical 
Schedule
2) Based on prelim info, 
does Subject generally meet 
eligibility criteria?
3) Invite Subject to participate in Study & 
Document Subject on 
Screening & Enrollment Log 
4) Consent Process 
Successful?
6) Subject meets all 
Eligibility criteria?YES
NO                 
YES- collect pre-op clinical data
8) Continue Post-op 
Follow-up NONo documentation 
needed
           Document as Screen Failure in Screening & 
Enrollment Log
YES
5) Subject Enrolled – Subject 
Identification Number Allocated
7) Surgery 
completed with 
assigned 
instruments
YESComplete 
Withdrawal CRF NO                 
NO Replace SubjectNO
  
  
Confidential DePuy Synthes Joint Reconstruction 
Revision Date: 19Feb-2018                                                                     Protocol: CIP [ZIP_CODE] REV B 
                                                                         Page 22 of 58 
 8.2.3Subject Identification Numbering 
The database assigns  Subject ID numbers after consent is obtained.  
 Each site is identified uniquely , e.g., 01-, 02- through 04, followed by [ADDRESS_578039] (3) three Subjects enrolled at Site 
#[ADDRESS_578040] Screening & Enrollment Log.   In the instance of a Subject being enrolled, a number assigned and subsequently the Subject is 
deemed ineligible prior to receiving the ATTUNE kn ee, the Subject will be recorded as a screen failure 
on the screening/enrollment log. Once a Subject identification number is assigned, it may not be 
reused.  Refer to Sections 8.[ADDRESS_578041] Participation and 8.4.1 Enrollment 
Replacement Rules.  
 
Study Procedures 
This section is applicable to individuals who ha ve undergone screening, have signed an Informed 
Consent Document, and have otherwise been found eligible to participate in this study per the Protocol’s Inclusion/Exclusion criteria. This sect ion details the pre-operative, operative, and post-
operative management of Subjects. Visit evaluations include  radiographic evaluations. Sample Case 
Report Forms (CRFs) are located in Exhibit A.  eCRFs must be submitted to DePuy Synthes Joint Reconstruction as outlined in Section 12.7 Case Re port Form Completion and Data Subm ission.                                 
       
8.3.1Subject Evaluation Tools 
No Patient Reported Outcome Measures are included in this study. 8.3.2Pre-operative Management 
Prior to surgery, the evaluations in Table 8-[ADDRESS_578042].  The 
interval for obtaining pre-op assessments is - 180 da ys to day 0 (day of surgery) as designated on the 
Time & Events Table 2.1. The pre-surgery management of each Subject enrolled in this investigation will be according to the standards of care used at the study site.   
Table 8-2: Pre-operative Da ta Collection and eCRF 
Evaluation Details of Evaluation 
Subject History For all Subjects  the Investigator or designee must confirm consent has been 
given, record the Subject’s demographic details and details of their p revious 
medical history, and confirm eligibility on Subject History eCRF.   
Radiographs Pre-operative radiograph s will be obtained.  
  
  
Confidential DePuy Synthes Joint Reconstruction 
Revision Date: 19Feb-2018                                                                     Protocol: CIP [ZIP_CODE] REV B 
                                                                         Page 23 of 58 
 8.3.3Intra-operative Management 
The surgical process is to fo llow site standard of care. 
This investigation allows the Investigator to foll ow their current standard of care with respect to 
patellar resurfacing. Specifically the Investigator can choose to: 
xResurface the patella 
xLeave the patella unresurfaced. 
 This investigation does NOT permit the Inve stigator to use TruMatch (or any other PSI 
instrumentation) or CAS for any Subjects, whether they are in the RUI or SUI arms of the study.  Products supplied by [CONTACT_453307]’s instructions 
unless an alternative technique is medically necessary.  
 
Each Investigator or designee will collect inform ation as noted in Table 8-[ADDRESS_578043] procedure and will continue unt il the room is cleaned up and ready for the next 
case.  
 Table 8-3: Intra-operative Data Collection and eCRFs 
Evaluation Details of Evaluation 
Operative Details  
eCRF For all Subjects , detailed surgical information and time information 
relating to the duration of 4 key elements of the surgical procedure 
will be recorded on the Operative Details eCRF.   These 4 elements 
are OR Set Up, Anesthetic, Surgery & Clean Down. Definitions of each 
element will be provided as part of the training for individuals who 
will be capturing time data. Note there is likely to be overlap in time 
between some of these elements (possible scenario illustrated 
below).  
 
1. OR Set Up
2. Anesthesia
3. Surgery
4. Clean Down
 
 
In addition to the star t and stop times for the 4 key elements , the 
occurrence of various incidents that can introduce delays or interruptions to the surgical flow will also be recorded.  
  
Confidential  DePuy Synthes Joint Reconstruction  
Revision Date: 19Feb -2018                                                                     Proto col: CIP [ADDRESS_578044] codes 
and catalog numbers can be found on pre-printed  labels p rovided in 
the sterile implant boxes.     
Retain a copy of each label to facilitate data entry into the eCRF  
Intra -operative 
Complications  
(if applicable)  
Adverse Event eCRF In the event of an intraoperative complication , an Adverse Event  
eCRF is completed. An intra -operative complication is defined as a 
complication that occurs between the start of anesthesia  and up to 
the time the Subject  is moved  to the recovery room. Complete a 
separate f orm  for each intra -operative complication.   
8.3.[ADDRESS_578045] -operative management is at the discretion of the  Principal Investigator  [INVESTIGATOR_453278]’s standard of care .  
 
The one(1) postoperative  study follow -up visit will be conducted according to the Time and Event s 
Table  2.1.   Each Investigator or designee will collect information as no ted in Table 8 -4 below.   At this 
visit r adiographs will be collected as detailed in the Radiographic Protocol (Exhibit F).  An independent 
radiographic reviewer (IRR) will evaluate all radiographs. Copi[INVESTIGATOR_453279] s upon request.  
 
 Table 8-4: Post -operative Data Collection and eCRFs  
Evaluation  Details of Evaluation  
Radiographs  For all Subjects  post-operative radiographs will be obtained.   
End of Study 
Completion or 
Subject 
Withdrawal  For all Subjects  the Investigator or designee must complete an End of 
Study/ Subject Withdrawa l eCRF to confirm  the Subject is no longer in the 
study.   
Post -operative 
Complication (s) 
(if applicable)  
 In the event of a  post -operative  comp lication  an Adverse Event  eCRF is 
completed. A  post -operative complication is defined as a complication that 
occurs at any time  from the time the Subject is in the recovery room up 
through the time a Subject withdrawal form  is submitted ending the Subject’ s 
study participation.  Complete a separate f orm  for each post -operative  
complication.   
 
8.3.5 Radiographic Procedures  
Weight bearing l ong-leg, hip -to-ankle  (51”  = 129.54  cm) Anteroposterior (AP) radiographs  will be 
taken , as well as standard AP and lateral vie w radiographs, following the detailed instructions 
presented in the Radiographic Protocol ( Exhibit  F).  While Patellar Skyline/Merchant view radiographs  
may be standard of care at some sites, they  are not a requirement of the study and they do not need 
to be submitted to the IRR.    All radiographs must  be de -identified  by [CONTACT_453308]  (IRR).  
  
Confidential DePuy Synthes Joint Reconstruction 
Revision Date: 19Feb-2018                                                                     Protocol: CIP [ZIP_CODE] REV B 
                                                                         Page 25 of 58 
  
8.3.6Management of Bias 
To avoid potential bias and ensure consistency, an Independent Radiographic Reviewer (IRR) will be 
used to evaluate the post-op [ADDRESS_578046] PHI information removed prior to assessment by [CONTACT_453309]. Data from the IRR radiographic evaluations (not the Investigato rs) will be used for determination of radiographic 
success criteria. Details of the radiographic asse ssment and means of submitting radiographs for 
review are detailed in Exhibit F, the Radiographic Protocol. 
Process for Discontinuation of Subject Participation 
A Subject is considered enrolled after signing the Informed Consent Document, as described in  Section 
5.3, Definition of Valid Subject Enrollment.  Su bject participation may discontinue through screen 
failure, withdrawal, or death. In all instances of  Subject discontinuation after obtaining Informed 
Consent, an End of Study/Withdrawal eCRF is requir ed to be submitted to the Sponsor supporting the 
study Subject’s study discon tinuation/withdrawal.   
 
8.4.1Preoperative Screen Failures/Withdrawals 
 
A Subject may withdraw consent at any time during th e study, even before surgery. The Investigator 
may withdraw the Subject preoperatively for safety reasons due to eligibility, for example, a patient 
may become pregnant during the window betw een giving consent and the planned surgery.  
 In all instances when a Subject is declared a screen failure , the Subject Screening and Enrollment Log 
must be updated to reflect that Subject’s removal/withdrawal from the study.  Occasionally, a screen failure (after obtaining consent) will also require and an End of Study/Withdrawal eCRF submitted to DePuy Synthes.  Please refer to table 8-5 for further guidance. 
  
  
Confidential DePuy Synthes Joint Reconstruction 
Revision Date: 19Feb-2018                                                                     Protocol: CIP [ZIP_CODE] REV B 
                                                                         Page 26 of 58 
 Table 8-5: Pre-operative Screen  Failure/Withdrawal examples 
Screen Failure   Potential Subjects determined to be ineligible for study participation 
preoperatively, and should not be implanted with study device. 
Before consent and before surgery,  
patient is determined to be ineligible  Update Screening/Enrollment Log  as 
“Screen Failure” and document 
reason Do not 
continue  
After consent and before surgery,  
Subject is determined  to be ineligible Update Screening/Enrollment Log  as 
“Screen Failure” and document 
reason   
Submit Subject History  and End of 
Study /Withdrawal eCRFs  to 
Sponsor Do not  
Continue 
Subject Withdrawal   Potential Subject withdraw s consent prior to receiving the study implant.   
After consent but before surgery,  
patient withdraws consent  Update Screening/Enrollment Log   
as “Withdrawal” and document 
reason  
Submit Subject History  and End of 
Study /Withdrawal eCRFs  to 
Sponsor Do not 
continue 
8.4.2Intra-operative Withdrawal 
The Investigator may withdraw the Subject intraoperatively for safety reasons, for example, it may 
become clear that the patient is not suited to receive the implant to be used for the study or the 
surgeon did not used the assigned instruments for whatever reason.  Please refer to table 8-6 for further guidance.    
  
Confidential DePuy Synthes Joint Reconstruction 
Revision Date: 19Feb-2018                                                                     Protocol: CIP [ZIP_CODE] REV B 
                                                                         Page 27 of 58 
 Table 8-6: Intraoperative Withdrawal example 
Intraoperative   Withdrawal:  Potential Subjects to be withdrawn from study participation 
intraoperatively. 
Intraoperatively 
determined to be 
ineligible  (example, 
ATTUNE primary implant 
not suitable) Update Screening/Enrollment Log  as “Intraoperative 
Withdrawal” and document reason  
Submit Subject History,  and End of 
Study /Withdrawal  eCRFs  to Sponsor 
Inform Subject that they were withdrawn  Do not 
continue  
Intra operatively the 
assigned instruments are 
not used  to perform the 
proximal tibia and/or distal femoral resectio
ns Update Screening/Enrollment Log as “Intraoperative 
Withdrawal” and document reason    
Submit Subject History, Operative Details, Device 
Log and End of Study/Withdrawal  eCRFs  to 
Sponsor .  Submit Adverse Event as applicable. 
Inform Subject that they were withdrawn Do Not 
continue  
Intraoperatively the 
ATTUNE   implant is 
attempted but not 
retained  Update Screening/Enrollment Log  as “Intraoperative 
Withdrawal” and document reason  
Submit Subject History, Operative Details, Device 
Log and End of Study/Withdrawal  eCRFs  to 
Sponsor . 
Submit Adverse Event as applicable.  
Inform Subject that they were withdrawn Do Not 
continue  
 
8.4.3Enrollment Replacement Rules 
Since Subjects are enrolled at the time of consent,  any Subject that is withdrawn preoperatively or 
intraoperatively prior to receiving the study implan t will be replaced with subsequent Subjects.  
Overall, the number of Subjects wh o received an ATTUNE implant using a study device (with either 
the RUI or SUI instrumentation), across all sites must meet the sample size of 88. 
8.4.4Postoperative Withdrawal 
A postoperative withdrawal is a Subject who has signed the Informed Consent Document, has 
received an ATTUNE implant using a study device (w ith either the RUI or SUI instrumentation), and is 
later withdrawn from study participation (i.e., withdrawal of consent, revision, death, etc.). Please 
refer to table 8-7 for further guidance.  
 
All data obtained up to the date of withdrawal will be included in the clinical analysis.   
  
  
Confidential  DePuy Synthes Joint Reconstruction  
Revision Date: 19Feb -2018                                                                     Proto col: CIP [ZIP_CODE] REV B  
                                                                         Page 28 of 58 
  
Table 8-7: Post -operative Withdrawal Examples  
Example  Action  Follow -Up 
Subject 
withdraws 
consent  • Study site documents Subject’s request 
for withdrawal from study.  
• Complete End of Study/Withdrawal  
eCRF  
• Update Screen/Enrollment Log . Do not continue  
Death • Complete Adverse Event  eCRF  
• Complete  End of Study/Withdrawal  
eCRF 
• Update Screen/Enrollment Log  Do not continue  
Revision  See Section 8.4. 5 and Table 8-8 Revision/Re -
Operation Examples  Do not continue  if metal tibial 
base or femoral component 
revised .  Continue to follow  if 
neither the metal tibial or 
femoral components have been 
revised.   
8.4.5 Revisions  / Reoperations  
A revision is defined as a surgical procedure of the affected knee where one or more of the TKA 
components (femoral and/or tibial base, poly ethylene insert, or patella polyethylene resurfacing 
component) are removed .  Should it be necessary for the Subject to undergo a revision of either the 
femoral or metal tibial base components  between the date of the enrollment and the completion of 
the st udy data acquisition, the Subject is to be withdrawn from study participation.  Thus, both an 
Adverse Event (AE) eCRF and a n End of Study  eCRF would be completed.  If possible, long leg x -rays 
should be captured prior to revision to permit analysis of the primary objective . 
 
A re-operation  is defined as any surgical procedure of the affected knee in which no TKA components 
are removed.  These subjects are not to be withdrawn .  An Adverse Event (AE) eCRF must be 
completed.  Several examples for revision/reop erations are shown in Table 8-8.   
 
  
  
Confidential  DePuy Synthes Joint Reconstruction  
Revision Date: 19Feb -2018                                                                     Proto col: CIP [ZIP_CODE] REV B  
                                                                         Page 29 of 58 
  
Table 8-8: Revision/Re -operation Examples  
Revision  A surgical procedure of the affected knee where one or more of the TKA 
components (femoral and/or tibial base, polyethy lene insert, or patella 
polyethylene resurfacing component) are removed .    
 
If either femoral or  metal  tibial  base  components are revised, the Subject is to 
be withdrawn from study participation.  
Example  Actions  Follow Up  
Removal or revision of either metal tibial 
base and/or femoral component  Complete Adverse Event  eCRF  
Complete End of Study/ Withdrawal  
eCRF  Do not 
continue  
Tibial polyethylene exchange   Complete Adverse Event  eCRF  Continue  
Revision of a patella which was resurfaced 
in the index TKA  Complete Adverse Event  eCRF  Continue  
   
Re-operation  Any surgical procedure of the affected knee in which no TKA components 
(femoral and/or tibial base, polyethylene insert, or patella polyethylene 
resurfacing component) are removed.  
Example  Actions  Follow Up  
Irrigation & debridement without tibial 
insert exchange  Complete Adverse Event eCRF  
 Continue  
Resurfacing of previously unresurfaced 
patella  Complete Adverse Event eCRF  
 Continue  
8.4.[ADDRESS_578047] of communications and/or 
attempts at communications in the source documentation. This record will b e used to obtain an 
indication or report on the current status of the study device (e.g., still in place and functioning 
satisfactorily; painful; revised; etc.).   
 
A Subject can be classified as “lost -to-follow -up” and  withdrawn from the study  only after  the visit 
window has closed and  the site has documented  in the medical record  at least t wo (2) unsuccessful 
attempts of contact .   Please refer to table 8 -9 for further guidance.  
  
  
Confidential  DePuy Synthes Joint Reconstruction  
Revision Date: 19Feb -2018                                                                     Proto col: CIP [ZIP_CODE] REV B  
                                                                         Page 30 of 58 
 Table 8-9: Recommended Con tact Attempts  
If Then  
A response is not received from phone calls  the Investigator should send a   letter to the 
Subject explaining the follow -up agreement per 
the informed consent.  
A response is not received from the Investigator’s 
letter  and/or all atte mpts to contact [CONTACT_453310]/ Withdrawal  eCRF will be 
completed and will specify why t he Subject is no 
longer participating in this study.  
  
Confidential DePuy Synthes Joint Reconstruction 
Revision Date: 19Feb-2018                                                                     Protocol: CIP [ZIP_CODE] REV B 
                                                                         Page 31 of 58 
 9RISK ANALYSIS 
Adverse Event Determination 
Adverse Event determination will be done by [CONTACT_079], or appropriate designee. 
Non-Reportable Adverse Events - Sponsor ONLY 
There are immediate post-operative events that ar e changes from the baseline condition of the 
Subject, but are expected events resulting from th e surgery. If these events occur, they should be 
recorded in the Subject’s medical record per standa rd medical practice, but it is not necessary to 
report them as AEs in the eCRF or to the Sponsor (please refer to Exhibit E-2 for listing of Non-
reportable AEs).   
Study Related Risks / Reportable Adverse Events 
Any surgical procedure poses a potential risk and th e procedures undertaken as part of this clinical 
investigation are no exception.   The surgical risks associated with the use of the Single Use Instruments for implanting the ATTUNE 
cemented primary TKA system are similar to those with the Re-usable instruments for implanting the ATTUNE cemented primary TKA system when used for the same clinical indication.   Additionally, the 
surgical risks are the same whether or not the Subject participates in this study for a number of 
reasons:   
xIt is assumed that the Investigator and patient ha ve mutually decided that primary TKA is an 
appropriate treatment for the patient’s condi tion and that the patient would have a TKA 
whether or not they choose to take part in this study; 
xThe same implant is used with both RUI and SUI instrumentation; 
xBoth types of instruments have to meet the same design control requirements/standards 
prior to market availability as do all surgical instruments on the market; 
xParticipating Investigators in this study are already implanting the ATTUNE TKA system with 
the re-usable instruments and will obtain training on the single use instruments prior to enrolling study Subjects. 
 Study related risks are categorized as those anticipate d to be related to general surgical risks, total 
knee arthroplasty risks, or those potential ri sks associated with the study implant system. 
Unanticipated Adverse Events  may occur as well.   
 
This protocol requires each site to report AEs, SAEs, ADEs, and SADEs to their respective IRB/EC per their IRB/ECs respective requirements  A summary of risks is described below, please refer to the printed IFU for additional details (Exhibit 
D).  A.General Surgical Risks  
  
Confidential  DePuy Synthes Joint Reconstruction  
Revision Date: 19Feb -2018                                                                     Proto col: CIP [ADDRESS_578048] -operative adverse events can occur with any surgery  and include, but 
are not limited to:   
• Anesthetic complications/reactions  
• Bleeding and/or excessive blood -loss 
• Transfusion rea ction  
• Post -operative infection  
• Vascular injury  
• Delayed wound healing  
• Deep vein thrombosis (DVT)  
• Nerve injury  
• Death  
 
B. Risks Associated with Total Knee  Arthroplasty Procedure/Study Device /Instruments   
 
Potential adverse events associated with primary total knee arthroplasty include, but are not limited 
to: 
• Early or late loosening of the prosthetic component(s)  
• Tibial subsidence  
• Bending, cracking, fracture, deformation of the prosthetic components  
• Excessive w ear of the polyethylene articulating surface  
• Progres sive bone resorption (osteolysis) as a result of foreign -body reaction to wear debris  
• Early or late infection  
• Delayed wound healing  or wound dehiscence  
• Pain  
• Dislocation or joint instability of the knee  
• Subluxation of the knee  
• Flexion contracture  
• Varus -valgus deformity  
• Malalignment  
• Decreased range of motion  
• Leg length discrepancy  
• Soft tissue impi[INVESTIGATOR_453280]  
• Bone fracture (s) 
• Nerve damage  
• Localized s welling  
• Vascular injury  
• Temporary or permanent neuropathies  
• Cardiovascular disorders including venous thro mbosis, pulmonary embolism, or myocardial 
infarction  
• Histological reactions resulting in inflammation  
• Metal sensitivity  
• Corrosion of metal components (the significance and long -term implications are uncertain 
and await further clinical evidence and evaluat ion) 
• Re-usable or single use i nstrument breakage  
  
Confidential DePuy Synthes Joint Reconstruction 
Revision Date: 19Feb-2018                                                                     Protocol: CIP [ZIP_CODE] REV B 
                                                                         Page 33 of 58 
 
Minimization of Risk 
Risks have been minimized by [CONTACT_453311] (total knee arthroplasty surgical 
instruments) to be similar to commercially available total knee arthroplasty surgical instruments used for the same indication. The ATTUNE surgical instru ments have been functionally tested to verify 
performance characteristics and biocompatibility.  In  addition, only trained orthopaedic surgeons with 
expertise in treating this condition will participate in this study. 
Investigators should refer to the ATTUNE implant system package insert for additional information 
and instructions for use (Appendix D) and the surgical technique (Appendix B).  The Sponsor will further minimize the identified and/or emergent risks throughout the study, by 
[CONTACT_453312] s and adverse effects.  All SAEs , SADEs, ADEs, UADEs and [LOCATION_003]DEs 
will be reviewed and evaluated by [CONTACT_453313]. 
 
Benefit Analysis 
There are no potential benefits to study Subjects from participation in this study. The knowledge 
gained from this investigation may help future TKA patients. 
 Adverse Event  
9.6.1Categories and Definitions 
Table 9-1: Adverse Event Categories 
ADVERSE 
EVENTS Non-Device 
Related Device- and/or Procedure-related 
Non -Serious Adverse Event 
(AE) Adverse Device Effect 
(ADE) 
Serious  Serious Adverse 
Event  
(SAE)  Serious Adverse Device Effect 
(SADE) 
Anticipated Unanticipated 
Anticipated Serious 
Adverse Device Effect 
(ASADE) Unanticipated Serious 
Adverse Device Effect 
([LOCATION_003]DE) 
 
Table 9-2: Adverse Event Definitions 
Term Details 
Adverse Event 
(AE)  Any untoward medical occurrence, unintended disease or injury, or untoward 
clinical signs (including abnormal laboratory findings) in subjects, users or other 
persons, whether or not related to the investigational medical device .  
 
Adverse Event is synonymous with complication or medical event. 
  
Confidential  DePuy Synthes Joint Reconstruction  
Revision Date: 19Feb -2018                                                                     Proto col: CIP [ZIP_CODE] REV B  
                                                                         Page 34 of 58 
 Term  Details  
Serious 
Adverse Event  
(SAE)  
 An Adverse Even t that:  
• leads to death,  
• leads to a serious deterioration in the health of the subject that  
o resulted in a life –threatening illness or injury,  
o resulted in an impairment of a body structure or a body function,  
  required in -patient hospi[INVESTIGATOR_453281],  resulted in medical or surgical intervention to prevent  
  permanent impairment to body structure or a body function,  leads to  
  fetal distress, fetal death or a congenital abnormality or birth defect.  
 
Note:   Planned  hospi[INVESTIGATOR_113617] a pre -existing condition, or a procedure 
required  by [CONTACT_10396], without serious deterioration in health, is not considered a 
serious  adverse event.  
Adverse 
Device Effect  
(ADE)  An adverse event related to the use of an investigational me dical device.  This 
definition includes any event resulting from insufficiencies or inadequacies in the 
instructions for use or the deployment of the device. This definition includes any 
event that is a result of a user error.  
Anticipated 
AE An effect whic h by [CONTACT_5942], incidence, severity or outcome has been previously  
   identified in the Instructions for Use for the medical device . 
Anticipated 
Adverse 
Device Effect 
(AADE)  An adverse event related to the use of an investigational medical device  is 
previously  identified in nature, severity, or degree of incidence in the current 
version of the Instructions for Use .  This definition includes any event resulting 
from insufficiencies or inadequacies in the instructions for use or the deployment 
of the devic e. This definition includes any event that is a result of a user error . 
Unanticipated 
Adverse 
Device Effect 
(UADE)  An adverse event related to the use of an investigational medical device  not 
previously identified in nature, severity, or degree of inciden ce in the current 
version of the risk analysis report .  This definition includes any event resulting 
from insufficiencies or inadequacies in the instructions for use or the deployment 
of the device. This definition includes any event that is a result of a user error . 
Serious 
Adverse 
Device Effect  
(SADE)  An adverse event related to the use of an investigational medical device that has 
resulted in any of the consequences characteristic of a serious adverse event .  
 
Anticipated  
Serious 
Adverse 
Device Effect 
(ASADE)  
 A serious adverse device effect which by [CONTACT_5942], incidence, severity or 
outcome has been identified in the curr ent version of the Instructions for 
Use/risk analysis report .  This definition includes any event resulting from 
insufficiencies or inadequacies  in the instructions for use or the deployment of 
the device. This definition includes any event that is a result of a user error . 
  
Confidential DePuy Synthes Joint Reconstruction 
Revision Date: 19Feb-2018                                                                     Protocol: CIP [ADDRESS_578049] 
([LOCATION_003]DE)  
 A serious adverse device effect which by [CONTACT_5942], incidence, severity or 
outcome has not been identified in the current version of the risk analysis.  This 
definition includes any event resulting  from insufficiencies or inadequacies  in the 
instructions for use or the deployment of the device. This definition includes any 
event that is a result of a user error . 
 
Site 
Awareness  
(Date of AE 
Awareness) The day, month and year that the study site becomes aware of information from 
any source that reasonably suggests th at an Adverse Event has occurred.   
 
Note: This date may or may not correspond to the date of onset.  The date of 
awareness is critical to reporting timelines (see Section 9.8). 
Adverse Event Reporting Guidelines 
9.7.1AE Reporting by [CONTACT_453314], a record  including details of site awareness, the nature, 
onset, duration, seriousness, relationship to the device, relationship to the procedure, treatment 
given (if any) and outcome, will be entered into the subject’s eCRF.   
 For this study, only serious AEs and those AEs relate d or possibly related to ei ther the device and/or 
the procedure are to be reported to the SPONSOR (Please see Figure 9-1).  
   
The outer circle (Figure 9-1) represents all AEs that could possibly be observed.  For this protocol, not 
all AEs are required to be reported.  The below list are the reportable AE’s that must be recorded on 
the eCRF and submitted to the Sponsor by [CONTACT_453315]:   
  
xAny AE classified as ‘ Serious’  (SAEs, SADEs, SUADEs)  to include Serious  procedure related AEs 
– report to Sponsor as soon as able but no later than 72 hours from site awareness* . 
xAll UADEs – report to Spon sor as soon as able but no later than 72 hours from site 
awareness*.  
xAll non-Serious Device Related (ADE) – rep ort to Sponsor as soon as able but no later than 2 
weeks from site awareness*.  
xAll non-Serious Procedure Related AEs, except for selected events (see Exhibit E-2: Non-
reportable list) -  report to Sponsor as soon as able but no later than 2 weeks from site 
awareness*.  
 *NOTE:  Not meeting the above reporting timelines to the Sponsor will result in a protocol deviation.  
 
  
Confidential DePuy Synthes Joint Reconstruction 
Revision Date: 19Feb-2018                                                                     Protocol: CIP [ZIP_CODE] REV B 
                                                                         Page 36 of 58 
  Figure 9-1: Adverse Event Repo rting for this Study Protocol 
 
 
 
 
 
Pre-existing medical conditions or symptoms report ed prior to the surgical event are not to be 
recorded as AEsE.  The only exception would be in the event there is an exacerbation of a pre-existing 
medical condition or symptom(s) in the post-operative  time frame, then an AE must be reported.   
  AEs are reported beginning from surgery and until Subject participation has ended (study completed 
or consent withdrawn). AEs must be followed to resolution, or until the study completion or consent withdrawal. When a Subject ends participation in  the study (either study completion or consent 
withdrawal) an AE must be designated either as “resolved” (end date must be provided), or as “ongoing.” 
 
Subjects should be encouraged to report AEs s pontaneously and may volunteer AE information at any 
time. At each evaluation, the Investigator will de termine whether a study reportable AE has occurred. 
If it is determined that such an AE has occurred , the Investigator should obtain all the information 
required to complete the appropriate AE form eCRF. If an event occurs at an outside institution, the 
Investigator should attempt to obtain, if possible, required AE information. 
 The Investigator will record the nature, severity, treatment and outcome of the AE, and will determine 
their association to the device and/or the study procedure. 
                                                           
E An example could be pre-existing contralateral kn ee osteoarthritis with a planned TKA intervention 
after the index knee surgery. 
 

  
Confidential DePuy Synthes Joint Reconstruction 
Revision Date: 19Feb-2018                                                                     Protocol: CIP [ZIP_CODE] REV B 
                                                                         Page 37 of 58 
 
Determination of AE Severity 
Refers to the intensity of the symptoms experience d by [CONTACT_453316], without regard to whether or not th e adverse event is classified as Serious. 
 
Please refer to Table 9-3 in determining intensity of symptoms of the reportable AE. 
 
Table 9-3: Definitions of Severity of AEs 
Term Description 
Severe 
Symptoms  The intensity of the symptoms  are severe and poorly tolerated, requiring 
intervention, and significantly affect activities of daily life; or place the Subject at immediate risk or harm. 
Moderate 
Symptoms The intensity of the symptoms are moderate.  Intervention is either noninvasive 
or not indicated.  Activities of daily living can be sustained.   
Mild Symptoms The intensity of the symptoms are mild, transient or  asymptomatic.  
Intervention is not indicated. Clinical or diagnostic observations only and no 
impairment of normal activity. 
Determination of Relationship to Device and/or Procedure 
The determination whether the AE is related to the device and/or procedure will be based upon 
whether a causal relationship between the device or procedure and the AE is at least a reasonable possibility, i.e., the relationship cannot be ruled out.  A causal relationship cannot be ruled out if, in 
the medical judgment of the Investigator, the effect  follows a reasonable temporal association with 
the use of the device and/or is confirmed by [CONTACT_453317], and/or the effect is not reasonably explained by [CONTACT_31388]’s clinical 
state.  
 Please refer to Table 9-4 in determining if an AE  is related to the study device or procedure. 
 
 Table 9-4: Definitions of Device-Relat edness and Procedure Relatedness for AEs 
Term Description 
Definite ly The relationship between study device or procedure and event does exist 
and is confirmed upon further in vestigation by [CONTACT_453318] ; however, 
other causes are possible  
Remote 
Possibility  There is minimal chance that a relationship exists between the study  device 
and/ or procedure  
Definitely Not  There is definitely no relationship between study device or procedure and 
the event  
  
Confidential DePuy Synthes Joint Reconstruction 
Revision Date: 19Feb-2018                                                                     Protocol: CIP [ZIP_CODE] REV B 
                                                                         Page 38 of 58 
 The AE Reporting flowchart (Figure 9-2) illustrates a series of questions a site must consider when 
determining whether a given clinical observation must  be reported and which AE’s do not need to be 
reported for this CIP.    
 
 
Figure 9-2: AE Reporting Flowchart 
 
NO
NO
YESYES YES
NONOClinical Observation
NEW CONDITION
Is it serious?New condition 
Or pre-existing 
condition?
Report to DePuy 
within 72 hrs of site 
awareness
& Ethics Comm
(per local requirements)PRE-EXISTING
Exacerbation of 
previous 
condition?
DO NOT REPORTIs AE related to device 
or procedure?YESIs observation included on 
“Do Not Report List”?
(Exhibit E)
Report to DePuy 
within 2 weeks of site 
awareness
& Ethics Comm
(per local requirements)
 
 
 
  
Confidential  DePuy Synthes Joint Reconstruction  
Revision Date: 19Feb -2018                                                                     Proto col: CIP [ADDRESS_578050] (IRB) / Ethics Committee (EC) Reporting.  
This protocol requires each site to report AEs, SAEs, ADEs , SADEs  and UADEs  to their respective 
IRB/EC, per their IRB/EC’s respective requirements . 
9.7.3 Regulatory reporting requirements  
Device related AEs will be reviewed  by [CONTACT_453319].   
  
Confidential DePuy Synthes Joint Reconstruction 
Revision Date: 19Feb-2018                                                                     Protocol: CIP [ZIP_CODE] REV B 
                                                                         Page 40 of 58 
 10STATISTICAL METHODOLOGY 
Statistical analysis will be performed using SAS  (SAS Institute Inc., SAS Campus Drive, Cary, North 
Carolina [ZIP_CODE]) software version 9.3 or higher.  Any further software that may be necessary will be described in the final study report.   
Study Design 
This study is a prospective, comparative, sequential , non-randomized, multi-center, controlled clinical 
investigation; see Section [ADDRESS_578051] udy design.  Reassignment of Subjects from one 
site to another may occur under circumstances defined in Section 7. The schema defined for reassigning Subjects is designed to keep RUI and SUI treatment groups balanced and to minimize 
potential bias.  
 
Treatment Assignment 
See Section 7. 
 Randomization will not be employed in this study.  Each site will consecutively enroll all RUI cases 
prior to enrolling consecutive SUI cases.      
Levels of Significance 
Unless otherwise stated, confidence intervals will be 2-sided 95% confidence intervals, and p-values below 0.05 will be deemed to be statistically significant. Unless otherwise stated, there will be no adjustment of significance levels because of testing multiple hypotheses. 
Interval Windows 
The pre-operative window will be from [ADDRESS_578052]-operative inte rval will be defined as 90 days plus or minus 60 
days.  
 
Table 10-1: Interval Windows 
Follow-up [days] 
Pre-Op  Surgery Immed 
Post-op 3 Month 
-180 to  0 0 1 to 29 30 to 150 
 
  
Confidential DePuy Synthes Joint Reconstruction 
Revision Date: 19Feb-2018                                                                     Protocol: CIP [ZIP_CODE] REV B 
                                                                         Page 41 of 58 
 
Handling of Missing Data 
Subjects with no post-op alignm ent data at [ADDRESS_578053] data which is collected will be utilized in analyses; no imputation of missing data 
will be performed. 
Primary and Secondary Endpoints 
The primary endpoint in this study is mechanical axis alignment, and the primary endpoint analysis 
will be to determine whether the alignment achieved with SUI instrumentation is non-inferior to the 
alignment achieved with RUI instrumentation. Mech anical axis alignment is defined as the angle 
between the line drawn from the center of the femo ral head through the center of the knee and  line 
drawn from the knee center to the ankle center.  Me chanical axis alignment will be measured from 
weight bearing long-leg (51”) Anteroposterior (AP) radiographs, taken approximately [ADDRESS_578054]-op 
(when Subject has reached full knee extension, within 5 degrees) and re ad by [CONTACT_453320]. The non-inferiority margin was set at 1.5o because the study team felt this was 
the maximum non-meaningful difference when thinki ng about absolute mechanical axis alignment 
differences between the RUI and SUI gro ups. A standard deviation between 1.5o to 2o is anticipated 
based on previous studies conducted by [CONTACT_453321] (Protocol 
ID #’s [ZIP_CODE], [ZIP_CODE]).   
The secondary endpoints are as follows: 
 
xTo compare alignment achieved with SUI vs. RUI of individual componen ts in the frontal and 
sagittal planes, specifically: distal femoral varus-valgus (FM) , proximal tibial varus-valgus (TM),  femoral component flexion and tibial slope. 
To compare the type and frequency of  adverse events, from the time of consent through to 
withdrawal of a Subject or the end of the st udy (includes pre-operative, intraoperative and 
early postoperative device-related adverse ev ents), between the SUI and RUI instrument 
groups.
 
 
Exploratory endpoints 
xTo compare SUI and RUI operating room times.  Specifically the duration of the four key steps 
in the procedure (possibly overlappi[INVESTIGATOR_007]) will be compared.  See Table 8-3. 
xTo determine whether SUI provides opportunity to reduce the incidence of minor procedural 
obstacles during the time in the OR.  
xTo compare Surgeon satisfaction of SUI instrumentation to RUI instrumentation. 
Hypotheses 
The null (H o) and alternate (H A) hypotheses are as follows:  
Ho: μSUI ≥ μRUI + 1.5o 
HA: μSUI < μRUI + 1.5o, 
where μRUI is the absolute value of mechanical axis al ignment angle sample mean of Subjects being 
operated upon using reusable instruments (RUI), and μSUI is the absolute value of mechanical axis 
alignment angle sample mean of Subjects being operated upon using single use instruments (SUI). 
 
  
Confidential DePuy Synthes Joint Reconstruction 
Revision Date: 19Feb-2018                                                                     Protocol: CIP [ZIP_CODE] REV B 
                                                                         Page 42 of 58 
 
Analysis Sets 
Below is a flow chart showing the analysis sets.  
Figure 10-1:  Analysis Populations Flowchart 
 
 
The primary analysis dataset will be the Per Protocol population.  Adverse event comparisons will be conducted using the Safety population. 
 
Sample Size Justification  
The primary endpoint will be a non-inferiority test  of absolute value mechanical axis alignment, 
comparing single use instrument result s with reusable alignment results.  
 A standard deviation of  1.870
o for this absolute value of mechanical axis was established in a previous 
DePuy Study (ID # [ZIP_CODE]). Assuming that this is a g ood estimate, a sample size of 35 per group will 
yield statistical power of 95% for a 1-sided test with a non-inferiority margin of 1.5o and α = 0.05.  This 
power estimate was calculated with the following SAS code:    6DIHW\3RSXODWLRQ
All cases that received the Attune device and the assigned instruments were used.   
&RQVHQWHG(QUROOHG3RSXODWLRQ
All cases consented to participate in this study 
3HU3URWRFRO3RSXODWLRQ
All cases from the Safety Population that  did not have major protocol violations.   ,QFOXVLRQ([FOXVLRQ9LRODWLRQV
1 ".QHHVPLQXV$VVLJQHGLQVWUXPHQWVZHUHQRWXVHG
1 ".QHHVPLQXV'LGQRWUHFHLYHWKH$WWXQHGHYLFH
LQFOXGLQJFDVHVWKDWGLGQRWKDYHVXUJHU\
1 ".QHHVPLQXV
Demographic & Adverse Event Analysis Adverse Event Narrative of cases that 
drop out of Safety Population 
Primary, Secondary, and Exploratory Analysis 
  
Confidential DePuy Synthes Joint Reconstruction 
Revision Date: 19Feb-2018                                                                     Protocol: CIP [ZIP_CODE] REV B 
                                                                         Page 43 of 58 
 Figure 10-2: SAS Code for Power Estimation 
proc power;   
twosamplemeans  
 meandiff = 1.5        
 stddev =1.87        
 groupweights=( 1 1)    
 power = .         
 alpha =0.05             
 sides =1           
 ntotal =70;        
run; 
 
This sample size is increased to 44 per group to account for attrition and possible problems with xray 
quality. 
Analysis Plan  
The primary endpoint is a non-inferiority test of mean absolute mechanical  axis angle, comparing 
single use and reusable instrument results with a non-inferiority margin of 1.5o using a 1-sided 
independent means t-test and α = 0.05.  The primary endpoint analysis null hypothesis will be rejected 
and non-inferiority will be concluded if th e 1-sided upper 95% confidence limit for μSUI - μRUI is less 
than 1.5o.   
 Preoperative demographics will be compared to  determine whether differences exist between 
treatment groups. Age and BMI will be compared using two-tailed independent means t-tests. Gender distribution will be compared with a Fisher’s exact test. 
 
Secondary analyses include: 
xTests of differences for individual component alignment in the frontal and sagittal planes, 
specifically: distal femoral varus-valgus (FM), proximal tibial varus-valgus (TM),  femoral component flexion and tibial slope using (independent means two-tailed t-tests). 
xThe types and frequencies of adverse events will be tabulated for all enrolled knees. The 
proportion of each complication will be compa red using a Fisher’s Exact Test (2 x 2 only) and 
Chi-square. 
 
Exploratory analyses will be conducted to see if SUI improves OR efficiency co mpared to conventional 
(RUI) instruments.  Exploratory analyses will also be conducted to investigate OR step times,  inter-
site differences in OR times, and issues that pote ntially introduced delays or interruptions in the 
surgical flow.   
 The Following Table presents a summary of the planned statistical tests:     
  
Confidential DePuy Synthes Joint Reconstruction 
Revision Date: 19Feb-2018                                                                     Protocol: CIP [ZIP_CODE] REV B 
                                                                         Page 44 of 58 
 Table 10-2: Planned statistical comparisons 
Comparison Purpose Expected Result 
Mean absolute mechanical axis non-
inferiority Primary efficacy  SUI Non -inferior to RUI 
Demographic comparisons Test comparability No difference 
Distal Femoral Varus-Valgus (FM) Secondary efficacy No difference 
Proximal Tibial Varus-Valgus (TM) Secondary efficacy No difference 
Femoral flexion  Secondary efficacy No difference 
Tibial slope Secondary efficacy No difference 
OR Efficiency Exploratory Analysis No difference  
Interim Analysis  
No interim analyses are planned for the purpose of stoppi[INVESTIGATOR_87545]. 
 
  
Confidential DePuy Synthes Joint Reconstruction 
Revision Date: 19Feb-2018                                                                     Protocol: CIP [ZIP_CODE] REV B 
                                                                         Page 45 of 58 
 11DEVICE DESCRIPTION  
All products used in this CIP have the appropri ate regulatory approval, FDA clearance/approval for 
commercial distribution and bear the CE mark.  The ‘devices’ under study are the surgical instruments. 
Instruments 
The instruments to be used in this study are detailed  below. Different sets of instruments will be used 
for each treatment group of this study. Please re fer to Exhibit B, Surgical technique for details. 
11.1.1Reusable Instruments 
The ATTUNE Reusable Instruments (INTUITION), as used  on the Control group, will be used on multiple 
patients, going through a process of decontamination  and sterilization after each surgical procedure 
in preparation for the next procedure. Reusable instruments are manufactured from a combination 
of engineering grade polymers and metals and are supplied non-sterile.   
11.1.2The ATTUNE Single Use Instruments (SUI)  
The ATTUNE Single-Use Instruments (SUI), which are also referred to as SOLO, as used on the 
Treatment group, will be used on a single patient and then disposed of. Single-Use instruments are 
manufactured from engineering grade polymers and s upplied sterile packed to hospi[INVESTIGATOR_600].  Kits consist 
of [ADDRESS_578055] ruments to perform a Total Knee Arthroplasty.  The 
pack details are outlined in Table 11-1 below. Once  a procedure is complete the packs of instruments 
are disposed of in clinical waste.  Details of the Packs and their function are outlined below. 
Table 11-1:  Detailed Instrument Information by [CONTACT_453322]:  Comple te set is delivered in 5 Packs 
1 – Primary Cuts    
      & Sizing Indication:  Enables distal femoral and prox imal tibial cuts, plus sizing of both 
femur and tibia. 
2 – Tibial  
      Preparation  Indication: Provided in 6 sizes, with one pack being opened once the patient 
anatomy is defined. 
3 – Femoral  
      Finishing Indication: Provided for both CR and PS configurations, each available in 6 
sizes. The specific size and configuration dictates which pack is opened. 
4 – Patella  
      Preparation Indication:  Used to size the patella and fix the patella implant component. 
5 – Pin Pack Indication:  Used for pi[INVESTIGATOR_453282]. 
Implants  
All components will be cemented.  The implants sp ecified in Table 11-2  below will be used for all 
study Subjects during this investigation. The inte nded purpose, indications, contraindications and 
population are described in the Instructions for Use (IFU), see Exhibit D. Product codes for each 
component are provided in Exhibit C.   
  
Confidential  DePuy Synthes Joint Reconstruction  
Revision Date: 19Feb -2018                                                                     Proto col: CIP [ZIP_CODE] REV B  
                                                                         Page 46 of 58 
 Table 11-2: Detailed Device Information for ATTUNE Implants  
Device 
Component  Component offerings   Details  
Femoral 
Components  Cruciate 
Retaining 
(CR) ATTUNE  femoral components are available in cruciate retaining (CR)  and posterior stabilized 
(PS) c onfigurations . The femoral components are manufactured from cast Co -Cr-Mo alloy 
conforming to ASTM standard F -75. They are available in lefts and rights. Fourteen sizes are 
available including standard sizes 1 -10 and narrow sizes: 3N, 4N, 5N, 6N. Femoral 
components are sterilized using gamma irradiation. They are available for cemented use 
only.    
The PS femoral components have a cam mechanism that articulates with a corresponding 
spi[INVESTIGATOR_277975].  Posterior 
Stabilized 
(PS) 
Tibial Bases  Fixed 
Bearing 
(FB) The FB tibial bases are manufactured from Co -Cr-Mo alloy conforming to ASTM standard F -
75. The proximal surface has a universal locking feature that is used for securing the FB tibial 
insert and permits up -sizing and downsizing. Ten sizes  are available including [ADDRESS_578056] a blasted 
finish to provide for enhanced cement fixation. FB Tibial Bases are sterilized using gamma 
irradiation. They are available for cemented use only.      
Rotating 
Platform 
(RP) The RP tibial bases are manufactured from Co -Cr-Mo alloy conforming to ASTM standard F -
75. The metal bases have a hollow, conical intramedullary stem. The flat superior surface of 
the base has a central hole continuous with the hollow conical medullary stem which receives 
the conical spi[INVESTIGATOR_453283]. The RP tibial insert component is not 
secured to the metal base, but rotates axially to maintain congruent contact [CONTACT_453323].  Ten sizes are available including [ADDRESS_578057] a blasted finish to provide for enhanced cement fixatio n. RP 
Tibial Bases are sterilized using gamma irradiation. They are available for cemented use only.     
Tibial Inserts  Fixed 
Bearing 
(FB) Cruciate 
Retaining 
(CR) The CR and PS tibial inserts are manufactured from UHMWPE and are available 
in sizes 1 -10 and  thicknesses from 5, 6, 7, 8, 10, 12, 14, 16, 18mm.   Additional 
thicknesses 20 & 22mm are available for the PS inserts. The distal surface has 
features that secure the insert to the FB tibial base.  Tibial inserts are sterilized 
using gas plasma sterilizat ion.  The PS insert has a spi[INVESTIGATOR_453284].  Posterior 
Stabilized 
(PS) 
Rotating 
Platform  
(RP Cruciate 
Retaining 
(CR) CR and PS inserts are manufactured from UHMWPE and are available in size s 1-
10 and thicknesses from 5, 6, 7, 8, 10, 12, 14, 16, 18mm.   Additional thicknesses 
20 & 22mm are available for the PS inserts.   RP inserts should be the same size 
as the selected femoral component.  The RP inserts articulate with the RP 
primary bases an d should be within [ADDRESS_578058] PCL.   The PS insert has a spi[INVESTIGATOR_453285].  Posterior 
Stabilized 
(PS) 
Patellae  Medial 
Offset  Patellar components are manufactured from UHMWPE. They are available in two styles, 
medialized dome and medialized anatomic. They are available in 5 sizes with proportionally 
increasi ng thicknesses from 8.5 to 10.5 mm. They are available for cemented use only.   Anatomic  
Bone 
Cement  FOR US SITES :  DePuy CMW  Antibiotic impregnated  bone cement is not cleared for use in primary joint 
replacement in the [LOCATION_002]  and will constitute  a protocol violation if it is used. See Figure 11 -1 for 
guidance.  
  
Confidential DePuy Synthes Joint Reconstruction 
Revision Date: 19Feb-2018                                                                     Protocol: CIP [ZIP_CODE] REV B 
                                                                         Page 47 of 58 
  
 
Figure 11-1 : Flowchart depi[INVESTIGATOR_453286]?
Does Site use DePuy 
Synthes Bone Cement for 
Standard of Care?Site Follow 
Standard of Care 
for Bone Cement 
Selection
Site MUST NOT 
use antibiotic 
bone cementYES, US Site
YESNONO, OUS Site
  
Confidential DePuy Synthes Joint Reconstruction 
Revision Date: 19Feb-2018                                                                     Protocol: CIP [ZIP_CODE] REV B 
                                                                         Page 48 of 58 
 12INVESTIGATOR RESPONSIBILITIES AND GOOD CLINICAL PRACTICES  
In conducting this medical device clinical invest igation the Investigator is responsible for:  
xEnsuring that a clinical invest igation is conducted according to the Declaration of Helsinki, 
applicable local regulations, the signed Clinical  Trial Agreement, and the Clinical Investigation 
plan;    
xProtecting the rights, safety, and welfare of  Subjects under the Investigator’s care; and 
xEnsuring the integrity of the data.  
 
Prior to the initiation of this clin ical investigation, the Principal Investigator [INVESTIGATOR_453287] (CIP) by [CONTACT_278021]. This signature [CONTACT_453332]. 
IRB/ Ethics Committee Approval 
All Principal Investigators must submit to their in stitution’s IRB/EC for initial review a copy of the 
clinical investigational plan (CIP) and a sample Informed Consent Document (ICD) provided by [CONTACT_429].  Many institutions request modification of the ICD to satisfy specific institutional requirements.  The use of a modified or unique In formed Consent Document is permitted provided 
that the document is reviewed and approved by [CONTACT_1034].  Additionally, all translated consent 
forms require IRB/EC approval.   
All Principal Investigators must submit the Clinical  Investigation for continuing review and any other 
additional required submissions to their IRB/EC acco rding to their IRB/EC’s policies and procedures.  
 Initial approval/favorable opi[INVESTIGATOR_277980]; originals 
of correspondence and approvals are to be filed by  [CONTACT_187641][INVESTIGATOR_453288].  
Informed Consent   
The Principal Investigator [INVESTIGATOR_453289].   
 If an Investigator perfor ms any study-specific data collection wi thout obtaining informed consent, the 
Investigator will report such use to the Sponsor and the reviewing IRB/EC within [ADDRESS_578059] Informed Consent. 
Protected Health Information 
The Principal Investigator [INVESTIGATOR_453290], processed, and confidentially maintained in accord ance with local data privacy regulation and law. 
 [LOCATION_002]:   The Principal Investigator [INVESTIGATOR_205668] e for taking the necessary steps to collect, 
process, and maintain confidentiality of the study Subject’s personal data in  accordance with data 
protection legislation including the Health Insurance Portability and Accountability Act of 1996 
  
Confidential DePuy Synthes Joint Reconstruction 
Revision Date: 19Feb-2018                                                                     Protocol: CIP [ZIP_CODE] REV B 
                                                                         Page 49 of 58 
 (HIPAA). Subjects will be asked to sign an Author ization for Release of Personal Health Information 
(PHI) for the purpose of this investigation. This  authorization may be combined with the ICD 
depending on local IRB preference.    
European Union:  The Principal Investigator [INVESTIGATOR_453291], 
process, and maintain confidentiality of the stud y Subject’s personal data in accordance with 
provisions of the national transposition of the EU Data Protection Directive 95/46/EC or local 
equivalent legislation, for Investigational sites outside of the US. Data protection consent will be 
obtained from the Subjects as part of the informed consent process.    Results from the Clinical Investigation may be publ ished. However, Subject confidentiality will be 
maintained at all times and it will not be possible to identify indi vidual Subjects from any data 
presented. 
Subject Discontinuation from the Clinical Investigation   
Any Subject is entitled to discontinue/withdraw from this clinical investigation for any reason without obligation and/or prejudice to further treatment. In addition, the  Investigator may decide for reasons of medical prudence, to withdraw a subject.  
The  Investigator will clearly document the date and reason(s) for the Subject’s discontinuation from 
this clinical investigation in the eCRF and submit to DePuy Synthes Joint Reconstruction. 
Please refer to Section 8.[ADDRESS_578060] Participation for further details. 
Source Documentation and Data Retention 
Each Investigator will maintain a complete, curren t and accurate case history (Source Documentation 
records) on each Subject according to the usual pr ocedure at the Site. Case histories medical records, 
including progress notes, hospi[INVESTIGATOR_1332], nurses’ notes, etc.  Additional documents to be retained  include: 
xSigned original Informed  Consent Form,  
xExecuted Authorization for Release of Personal Health Information (may be combined with 
Informed  Consent Form based on local IRB requirements) – not required outside [LOCATION_003].  
xCompleted Source Worksheets(if used), 
xResults of relevant diagnostic and laboratory tests, 
xIntraoperative and post-operative  complications and treatment, and 
xAny other relevant information or documentation pertaining to the condition of the Subject. 
 
The Investigator should retain copi[INVESTIGATOR_179171] (for at 
least [ADDRESS_578061] 3 years in the [LOCATION_002] after this clinical 
investigation is completed, or according to institutiona l policy if longer.  In addition, if the Investigator 
moves/retires, etc., s/he should provide DePuy Sy nthes Joint Reconstruction with the name [CONTACT_453333] ’ clinical investigation related records.
 The investigator agrees that the Sponsor’s employee s or designees will have the right to audit and 
review pertinent medical records relating to this clinical trial. 
  
Confidential DePuy Synthes Joint Reconstruction 
Revision Date: 19Feb-2018                                                                     Protocol: CIP [ZIP_CODE] REV B 
                                                                         Page 50 of 58 
 
Record of Device Inventory  
Not applicable as this is a post-market st udy on an FDA cleared/CE marked product.  
Case Report Form Comple tion and Data Submission 
Data will be captured within an electronic data capture system. 
Electronic Case Report Forms (eCRFs) will be used to  collect and submit all Subject data once a Subject 
is enrolled in the study. Investigative study sites are asked to  enter Subject data into the eCRFs 
preferably within [ADDRESS_578062]  was seen for their scheduled study visit. 
 
Role-specific training on eCRF completion are includ ed  via Learning modules and  are required to be 
completed by [CONTACT_737](s) and study support staff prior to initiating Subject enrollment. 
 
The eLearning will be assigned by [CONTACT_453324].    The personal data recorded on all documents, including copy documents, and within the EDC system, will be regarded as confidential. The Investigator will be responsible for the timing, completeness and accuracy of the details entered within the electron ic data capture system.   All data entered in the 
database must have source documents in the Subject’s medical records.  
 
There are no patient-reported outcome measures used in this study.   The protocol required data may be entered directly  into the respective eCRF within the electronic 
data capture system by [CONTACT_18370] .   The respective eCRFs must be fully completed 
for each Subject.  The Investigator’s electronic si gnature will be obtained within the EDC system once 
all study data has been entered, cleaned, and coded (a nd at interim analysis if  applicable).   Signoff 
can occur on a per form or per casebook level.  An y changes to the data will break the Investigator’s 
signature [CONTACT_453334]. 
 
Paper Source Worksheets may be provided and may be used (optional) to supplement data points 
that are not typi[INVESTIGATOR_453292]..  These data will then be required to be transferred directly to the eCRF within the electronic data capture system for submission to the Sponsor.  If paper Source Worksheets are used, they  must be stored in the Subject’s research record, 
as these will be considered source documents, please  refer to Section 12.5.  Any errors on paper forms 
should be crossed out with a single stroke, initiale d and dated. Typi[INVESTIGATOR_136541].  
 
The Investigator must record the Subject’s participation in this clinical investigation in the Subject’s 
clinic notes.  In addition, the Investigator must keep  a separate list of all Subjects entered into this 
clinical investigation showing each Subject’s name , date of birth and assigned Subject number (for 
identification purposes).  A Patient Information log will be provided in the Investigator Site File for this 
purpose and remain at the site.  The Investigator should retain copi[INVESTIGATOR_453293] 
(including source documentation, the informed  consent document and any other documents to 
  
Confidential DePuy Synthes Joint Reconstruction 
Revision Date: 19Feb-2018                                                                     Protocol: CIP [ZIP_CODE] REV B 
                                                                         Page 51 of 58 
 identify the Subjects) for at least 5 years after this cl inical investigation is comp leted.  In addition, if 
the Investigator moves/retires, etc., he should prov ide DePuy Synthes Joint Reconstruction with the 
name [CONTACT_453335]’ clinical investigation related 
records. 
 
Data queries will be generated by [CONTACT_453325], if applicable.  Resolution of 
the queries will be the responsibility of the Invest igator and investigation team members. Following 
completion of all data queries on each eCRF, the Investigator will be responsible for reviewing and 
confirming agreement to the data within the system.  The platform software has been validated in accordan ce with 21 CFR Part 11, European Commission’s 
Directive on Data Protection and US  Safe Harbor Certification. Prior to being released for data entry, 
validation of the study level components (i.e., data entry scre ens, associated edit checks and work 
flow) will be conducted in accordance with approv ed user acceptance testing procedures. Access to 
this system will be controlled so that only author ized users will have the ability to enter into the 
system. The system is considered a closed system according to 21 CFR Part 11 Electronic Records; 
Electronic Signatures.    
Protocol Adherence 
The Investigator (s) agree to conduc t the study in accordance with this protocol.  Prior to beginning 
the study, the Investigator (s) must sign the  protocol signature [CONTACT_3264]. 
 An Investigator must not make any changes in a study without first receiving approval from the 
Sponsor and IRB/EC, except when necessary to el iminate apparent immediate hazards to a Subject. 
 
With the exception of emergency situations, no deviat ions to this CIP will be permitted.  In the event 
of an emergency situation, the Principal Investig ator must notify their DePuy Synthes clinical 
operations contact [INVESTIGATOR_97318].  A full written report of the situation must be forwarded to the 
IRB/EC who approved the original CIP and DePuy Synt hes Joint Reconstruction within 10 working days 
of the event.   
CIP Amendments 
If it becomes necessary to amend the Clinical Inve stigation then the nature of the amendment will be 
agreed between the Sponsor and the Principal Inve stigator(s) and this will be recorded with a 
justification for the amendment.  The appropriat e IRB/EC, will be informed of any amendments.  
 
 Investigator Reporting Responsibilities 
In fulfillment of study related requirements, the Investigator is responsible for preparing and 
submitting complete, accurate, and timely reports as described below.  
  
Confidential  DePuy Synthes Joint Reconstruction  
Revision Date: 19Feb -2018                                                                     Proto col: CIP [ZIP_CODE] REV B  
                                                                         Page 52 of 58 
 Table 12-1: Investigator Reporting Responsibilities  
Report  Description  Action  
Withdrawal of 
IRB/EC approval  The Investigator will promptly notify the Sponsor of a 
withdrawal of approval by [CONTACT_3488]/EC  or of the 
Investigator’s part in an investigation with in 2 weeks . Preferably 
within 2 weeks  
Progress Report  If required by [CONTACT_5282]/EC, t he Investigator is responsible 
for submitting progress reports on the investigation to 
the reviewing IRB/EC.  As required per  
your IRB/EC  
Reports of 
deviations from the 
investigational plan  The Investigator will notify the Sponsor of any deviation 
from the Investigational Plan  as soon as able .  
 
The Investigator will notify the IRB/EC of any deviation 
from the Investigational Plan per the IRB/EC 
requirements.  Per IRB /EC 
requirements; 
at least annually  
Other  The Investigator will, upon request of a reviewing IRB/EC  
or Sponsor , provide accurate, complete, and current 
information about any aspect of the investigation.  As requested  
 
The Principal Investigator [INVESTIGATOR_277983] a q ualified associate(s) to complete one or more of the above 
functions. However, the Principal Investigator [INVESTIGATOR_277984], 
proper conduct of the study including obtaining Subject  Informed C onsent, compliance with this study 
plan, and the collection of all required data.  
 
  
  
Confidential DePuy Synthes Joint Reconstruction 
Revision Date: 19Feb-2018                                                                     Protocol: CIP [ZIP_CODE] REV B 
                                                                         Page 53 of 58 
 
Investigator Site File 
Each Investigator and all personnel from the invest igational site must main tain accurate, complete, 
and current information about all aspects of this Clinical Investigation. This includes documentation 
relating to the Investigator’s participation, Subject information and correspondence: electronic, written, and verbal, relating to any as pect of the clinical investigation.  
 
The records are maintained in the Investigator Site File consisting of, but not limited to, 
correspondence with other participating Investigat ors, the reviewing IRB/ EC, and the Sponsor.  
 Upon receipt of copi[INVESTIGATOR_453294] (otherwise 
known as the Study Protocol) from the Sponsor, th e Investigator will add the updated document and 
Revision Log to the Investigator File. The outdated version will be filed. 
Regulatory Requirements  
This clinical investigation is a post-marketing surv eillance study to obtain additional data. The devices 
are FDA cleared/approved and CE marked products cleared for sale by [CONTACT_453326](ies) in which this clinical investigation is to be conducted.   
Investigator Study Termination 
The Investigator may prematurely terminate the clin ical investigation at any time. Should this be 
necessary, the procedures will be arranged on an individual clinical investigation basis after review 
and consultation by [CONTACT_49249]. In terminating the clinical investigation, the Sponsor and the  
Investigator will assure that adequate consideration is given to the protection of the Subject’s 
interests, all documentation is archived per Sect ion 12.5 and the appropriate bodies such as the 
IRB/EC are informed as appropriate.   
  
Confidential DePuy Synthes Joint Reconstruction 
Revision Date: 19Feb-2018                                                                     Protocol: CIP [ZIP_CODE] REV B 
                                                                         Page 54 of 58 
 13 SPONSOR OBLIGATIONS 
IRB/EC Approval 
The Sponsor requires this Clinical Investigation Plan  to be submitted to the IRB/EC for initial review 
and approval before implementation at each site.  Additionally, all protocol amendments must be 
submitted to the IRB/EC for review and approval before implementation.  Each site is required to submit a copy of the IRB/EC initial approval.  Additionally, US sites are required 
to submit a copy of the IRB renewal(s), typi[INVESTIGATOR_453295], to the Sponsor for filing in the study’s Trial 
Master File.  The site is to maintain the original  documentation of the initial approval and annual 
renewals in the site’s Investigator Site File.   
Investigator Training, Pre-Investigational Visit 
Prior to enrolling Subjects in this study, the Inve stigator and/or appropriate site personnel will be 
trained on the study protocol to include: 
xthe general aspects of study administration, 
xall procedures in the protocol, and 
xthe procedure for e-data acquisition and transmission. 
 The Sponsor will be offering hands on training to supplement professional education of the surgeon on the implant and surgical instruments, as needed.   
 Study Monitoring 
Sponsor oversight will be maintained per Sponsor polici es and procedures.  On site monitoring will be 
done at the discretion of the Sponsor. Should a mo nitoring visit be required, the Sponsor will work 
with the site to determine the date(s).   
During the visit, the Sponsor and au thorized Sponsor representatives shall be given access to all study 
records, to include study Subject  medical records.    
All study Subjects are required to sign the Informed  Consent Document allowing access to and release 
of their personal health information.  
Labeling 
Refer to Exhibit D for Product Labeling. 
Sponsor Study Termination 
The Sponsor may prematurely terminate or suspend th e clinical investigation as a whole or at an 
individual investigational site for significant and documented reasons.  Reasons for premature termination or suspension include, but are not limi ted to safety, inadequate recruitment, Principal 
Investigator [INVESTIGATOR_453296], device related problems, alig nment with business strategy or administrative 
issues. 
  
Confidential DePuy Synthes Joint Reconstruction 
Revision Date: 19Feb-2018                                                                     Protocol: CIP [ADDRESS_578063] not yet had the surgical 
procedure would be treated as per their surgeon's standard practice using implants and instruments 
of the surgeon's choice. All enrolled Subjects who have received an ATTUNE implant within the study 
would continue to be cared for by [CONTACT_453327]/her standard of care. No further 
study-related procedures or d ata collection would occur.  
Sponsor Reporting Responsibilities 
The Sponsor is responsible for preparing and submit ting complete, accurate and timely reports per 
Section 9.6.3. 
Financial Agreement 
Funding of the clinical investigation will be  deta iled in  a separate agreement between the Sponsor 
and the Institution where the clinic al investigation is being conducte d and the Principal Investigator 
(where permitted by [CONTACT_453328]). 
Publication Policy and Public Disclosure 
The Sponsor is committed to publication of this st udy.  A multi-center publication will be completed 
prior to allowing individual sites to publish their own data.  Authorship  decisions will be aligned with  
the International Committee of Medical Journal EditorsF.  All manuscripts including data from this 
study will be reviewed and approved  by [CONTACT_1034], and each auth or, prior to any submission. All 
authors must disclose financial or personal affiliations that could be considered conflicts of interest. 
  
The sponsor will register this study  on www.clinicaltrials.gov  per  FDAAA regulations.   
Insurance 
The Sponsor will secure and maintain in full force an d effect, throughout the duration of the Clinical 
Investigation, clinical trial insurance in line with national regulations. The type of insurance for each 
participating site is detailed within the respective Clinical Trial Agreement or equivalent which will be executed before the start of Subject recruitment at that site.      
 
 
                                                           
F http://www.icmje.org/  
 
  
Confidential  DePuy Synthes Joint Reconstruction  
Revision Date: 19Feb -2018                                                                     Proto col: CIP [ZIP_CODE] REV B  
                                                                         Page 56 of 58 
 14 REFERENCES  
 
1. Krackow K.A. Serpe L. Phillips M.J. Bayers -Thering M. Mihalko W.M.  A new technique for 
determining proper mechanical axis alignment during total knee arthroplasty: Progress 
toward computer -assiste d TKA.Orthopedics.  22(7)(pp 698 -702), 1999. Date of Publication: 
1999.  
2. Wasilewski RC, Galante JO, Leighty R, Natarajan RN, Rosenberg AG. Wear patterns on 
retrieved polyethylene inserts and their relationship to technical considerations during total 
knee a rthroplasty. Clin Orthop; 299: 31 -43, 1994.  
3. Chauhan SK. Scott RG. Breidahl W. Beaver RJ. Computer -assisted knee arthroplasty versus a 
conventional jig -based technique. A randomised, prospective trial. J Bone Joint Surg,, 86 
B(3):372 -7, 2004 Apr  
4. Stulberg SD , Loan P, Sarin V: Computer -assisted navigation in total knee replacement: Results 
of an initial experience in thirty -five patients. J Bone Joint Surg, 24 -A Supplement 2: 90 -98, 
2002.  
5. Barrack et al: Component Rotation and Anterior Knee Pain after TKA. Clin  Orthop Rel Res,392: 
46-55, 2001.  
6.  Berger RA, Rubash HE, Seel MJ, Thompson WH, Crossett LS. Determining the rotational 
alignment of the femoral component in total knee arthroplasty using the epi[INVESTIGATOR_453297]. 
Clin Orthop Rel Res, 286:40 -7, 1993.  
7. Ishii Y. O hmori G. Bechtold J.E. Gustilo R.B. Extramedullary versus intramedullary alignment 
guides in total knee arthroplasty.Clinical Orthopaedics and Related Research.  (318)(pp 167 -
175), 1995. Date of Publication: 1995.  
8. Overdyk F.J. Harvey S.C. Fishman R.L. Ship pey F. Successful strategies for improving operating 
room efficiency at academic institutions. Anesthesia and Analgesia.  86(4)(pp 896 -906), 1998. 
Date of Publication: Apr 1998.  
9. Weinbroum A.A. Ekstein P. Ezri T.Efficiency of the operating room suite. Ameri can Journal of 
Surgery.  185(3)(pp 244 -250), 2003. Date of Publication: 01 Mar 2003.  
10. David M. Friedman, Suzanne M. Sokal, Yuchiao Chang, David L. Berger.  Increasing Operating 
Room Efficiency Through Parallel Processing. Ann Surg. 2006; January; 243(1): 10 –14. 
11. Ricketts D. Patterson M. Harries W. Hitchin D. Hartley J. An orthopedic  theatre timings survey. 
Annals of the Royal College of Surgeons of England.  76(3)(pp 200 -204), 1994. Date of 
Publication: 1994.  
12. Frost & Sullivan. European Markets for Orthopaedic  Surgical Instruments. 
www.researchandmarkets.com Jan 2007.  
13. www.healthcareaz.org/resources/res.aspx/Resource/resourceFilename/529/single_ use-
instruments.pdf  
14. Morrison J.M, Jacobs V.R: Replacement of Expensive, Single -use Instruments With Old -
fashioned Surgical Techniques for Improved Cost -effectiveness in Laproscopic Hysterectomy.  
15. Hamaguchi T, Noguchi -Shinohara M,  Nakamura Y, Sato T, Kita moto T. Opthalmic Surgery in  
Prion Diseases. Emergency Infectious Diseases. Vol.13. No.1. January 2007.  
16. Lau H: Endoscopic Extrapeitoneal Inguinal Hernioplasty: Single -use and Reusable Instruments. 
2006.15.109 -115.  
 
  
Confidential  DePuy Synthes Joint Reconstruction  
Revision Date: 19Feb -2018                                                                     Proto col: CIP [ADDRESS_578064] Organization 1415 5.  Second Edition 2011 -2-01.  Clinical investigation 
of medical devices for human subjects – Good clinical practice.  
  
Confidential  DePuy Synthes Joint Reconstruction  
Revision Date: 19Feb -2018                                                                     Proto col: CIP [ZIP_CODE] REV B  
                                                                         Page 58 of 58 
 15 CLINICAL INVESTIGATIONAL PLAN  EXHIBITS  
Exhibit  Description of Exhibit  
A Sample Case Report Forms  
B Surgical  Technique  
C Implant  Produc t Codes  
D Instructions for Use (IFU)  
E Adverse Events:  Tips & Pearls  
• Listing of Non -reportable  Adverse Events  
• Preferred Terms for Select TKA Related Adverse Events  
• Flowchart for AE reporting  
F Radiographic  Protocol  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 